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ABSTRACT 
For a peptide vaccine to be effective in generating an antibody response, it 
generally must incorporate both B cell epitopes, against which the antibody response is to 
be directed, and T cell epitopes, which are responsible for stimulating helper T cells. The 
first part of this work is concerned with the question, "How well can a T cell epitope 
replace the carrier protein from which it is derived?" To answer this question two studies 
were done: an initial, direct comparison between a protein (the Fab' fragment of murine 
monoclonal anti-f1uorescein antibody 9-40) coupled to hen egg lysozyme (HEL) and the 
sanle protein coupled to the immunodominant T cell epitope from HEL for BIO.A (H-2a) 
mice, along with negative controls, and a second, dose response study with fluorescein 
(FL) as the B cell epitope attached to a multiple antigenic peptide (MAP) version of this 
T cell epitope, along with positive and negative controls (HEL and a MAP in which the 
epitope sequence was replaced by glycine residues, respectively). This study showed a 
half-sigmoidal curve for the FL-(T epitope) immunogen, no response to the negative 
control except at the highest dose used, and a fairly constant and high response for both 
the experimental MAP and the fluoresceinated HEL. 
The initial study described above gave a very specific anti-idiotype response for 
the (9-40)Fab' -HEL construct. Another, follow-up study compming a peptide mimic 
based on an important idiotope, the third complementarity determining region of the 
heavy chain (the CDR-H3 loop), to the intact idiotype was also conducted. In this study 
the peptide mimic of the CDR-H3 loop was the B cell epitope; it was also coupled to 
HEL. The question being addressed was, "How well can an idiotope peptide mimic 
replace its parent idiotype?" BIO.A mice were immunized with (B epitope)-HEL, (9-
40)Fab' -HEL, (B epitope) + HEL mixed together, or just the B epitope. The essential 
issue was crossreactivity, and this was observed to increase with succeeding 
immunizations. Molecular dynamics simulations with generalized Born implicit 
sol vation or particle mesh Ewald electrostatics were also used to provide insight into the 
structural basis of idiotopic phenomena. 
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CHAPTER 1 
INTRODUCTION TO TAND B CELL EPITOPE MIMICRY: 
TERMINOLOGY AND IMPORTANCE 
The science of immunology has grown from a medical curiosity in the eighteenth 
century to one of the cornerstones of modem medicine, being intertwined with all 
infections, inflammation, cancer, aging, genetics, and even emotions - in short, with 
everything that determines whether a person is sick or healthy. From its beginnings as a 
separate field of study to the present day, vaccines have been a major aspect of 
immunology; indeed, the purpose of a vaccine is to stimulate the immune system to 
provide prophyllaxis or, more recently, therapy against a specific disease. Hence, a 
vaccine is really any immunogen that has been deliberately administered to elicit a 
prophylactic (or sometimes therapeutic) response without causing severe disease. 
Types of vaccines 
Classical vaccines are either live attenuated organisms (including viruses) or else 
are killed organisms and as such are poorly defined, chemically complex mixtures. With 
the rise of modem biochemistry it has become possible to identify the parts of the 
antigens that are recognized by the immune system. (As a matter of terminology, an 
antigen was initially defined as a substance that could evoke an immune response and 
was synonymous with imrnunogen. Usage has changed, however, so that nowadays an 
antigen is defined as a molecule that is capable of being recognized by the immune 
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system, whether or not it actually is, and an immunogen is a substance that can evoke an 
immune response.) These so-ca1Jed antigenic detenninants are also known as epitopes 
and are recognized by immunological biomolecules.* 
Because they are poorly defined, chemically complex mixtures, classical vaccines 
can and do eJicit immune responses against antigens that are not involved with protection. 
Worse, classical vaccines suffer from the fact that, for the most part, only organisms that 
can be grown in culture can be made into suitable vaccines. Identification of the 
protective epitopes allows subunit vaccines to be made with only the antigens involved in 
protective immunity or even with only just those epitopes; this can be especiaIJy useful 
with parasitic and cancer antigens. Such subunit vaccines can be prepared by genetic 
engineering methods or by chemical synthesis. Recombinant DNA technology can be 
used to prepare entire antigenic proteins. This is an advantage in cases in which the 
actual epitopes are unknown or vary from individual to individual within the population. 
A commercial example of this approach is a hepatitis B virus vaccine, which is produced 
in yeast cells (1, p. 110). However, purification of the antigen from the expression 
system can sometimes be difficult and there is the danger of immune reaction against 
residual host proteins (1), More recently, "naked" DNA vaccines have been used that 
code for the antigen in a plasmid construct (www.vical.com). These vaccines are 
effective and do not require purification of the antigen. 
Another approach would be the minimalist approach of peptide vaccines, using 
just the epitopes that are actually involved in immunity. Synthetic peptides as vaccines 
* Although not used in the remainder of this dissertation, other related tenns are paratope 
(the portion of an antibody or TCR that contacts the epitope), mimotope (a peptide mimic 
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are attractive in that they would be expected to have excellent safety margins. They are 
especially promising for cancer vaccines, where the entire antigen already is encoded by 
the host genome but the cancer cells escape immune detection. For peptides to be used as 
vaccines it is essential that the epitopes be known. For a T cel] dependent response, 
which is generally desirable since this type of response typically results in superior 
immunological memory, this requirement can be difficu1t due to the fact that the epitopes 
which a given antigen possesses wi}] vary from individual to individual, depending on 
their MHC haplotypes (discussed more below). In contrast, type 2 T cell independent 
responses rely on B cell receptor (membrane bound Ig) crosslinking to directly stimulate 
the B cells. (Type 1 T cell independent responses involve direct B cell stimulation via 
endotoxin.) 
MHC hap)otypes 
Genetic nomenclature can be confusing and this is especially so of immune 
system genes. Dozens of histocompatability loci have been genetically mapped to 
virtua]]y every mouse chromosome (2 p. 180); those that correspond to rapid graft 
rejection were initially designated as the H-2 locus. The H-2 locus is actually a complex 
of genes rather than a single locus and was accordingly called the major 
histocompatibility complex (MHC) to distinguish it from the many other minor 
histocompatibility loci that were associated with slow graft rejection. Within the wider 
H-2 complex - the MHC - are two major subcomplexes: the classical H-2 complex t and 
of a discontinuos epitope), and aggretope (the portion of an MHC-I or MHC-II protein 
that contacts the peptide). 
t The MHC and the H-2 locus were originally synonymous, but how can the H-2 complex 
encompass the H-2 complex? For this reason J have referred to the larger complex as the 
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the Tla complex (2). Both of these consist of several regions; the H-2 complex consists 
of regions designated as K, I, S, and D (Figure 1). The MHC is also divided into three 
so-called classes, coding for the class I, class II, and class III gene products. The S 
region of the H-2 complex encompasses the class III genes, which encode some 
complement proteins, as well as some genes for proteins that are not especially 
immunological (3, p. 75). The class I gene products include those of the entire Tla 
complex as weJl as the transplantation surface antigens responsible for graft rejection, 
initiaJIy used to define the MHC. The former proteins are hematolymphoid 
differentiation antigens. Only the latter proteins are what immunologists typically refer 
to as MHC class I (or MHC-I) proteins; they are also termed serologically defined (SD) 
antigens and exhibit extreme polymorphism. Consequently, the Tla proteins and others 
like them are termed class IB (or class Ib) proteins and are encoded by "class I-like" or 
"nonclassical" or "class I-related" genes, in contrast to the class IA proteins, which are 
the conventional, polymorphic MI-IC-I polypeptides. Those are the transplantation 
antigens K, D, and L, which are encoded by genes in the K and D regions of the H-2 
complex. (The L antigen is encoded in the D region.) Most class IB molecules are of 
unknown function. Both types of gene products associate noncovalently with another 
protein, ~2 microglobulin, which is encoded on another chromosome. Actually, when 
people speak of an MHC-I protein, they often mean the functional protein consisting of 
both the MHC class I gene product and ~2 microglobulin, rather than just the MHC-I 
MHC. Furthermore, in humans the MHC is known as the HLA complex for historical 
reasons, and the class 1 and class II genes also bear different names. However, since it is 
essentially the same (albeit polymorphic) molecule as for other species, I will use "MHC" 
throughout this dissertation instead of "HLA", even when referring or potentially 
refen4 ing to humans. 
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Figure 1. Schematic diagram of the MHC complex on mouse chromosome 17. For the 
purpose of this dissertation, the most important point is that the I region encodes the 
class II genes. Other class II genes encoding a proteasome complex, a peptide 
transporter, and other products are not shown for simplicity. Numerous other genes or 
pseudogenes are also present in the Tla, again not shown for simplicity. Adapted from 
(2) with corrections. 
gene product. In this case the class I polypeptide is termed the heavy chain and the ~2 
microglobulin the light chain. Furthermore, as if to add to the potential confusion, the K, 
D, and L antigens - the MHC-I polypeptides - are all essentially the same: they are all 
integral membrane glycoproteins ranging in molecular weight from 40 to 45 kDa, all 
have (in common with other class I proteins) three extracellular domains, a 
transmembrane domain, and a cytoplasmic domain, all share the same conserved 
interaction regions for CDS molecules (unlike the class IB proteins), all exhibit extreme 
polymorphisnl but only in their peptide binding domains, and all have the same function: 
in conjunction with ~2 microglobulin, to present a peptide fragment to a T cell receptor 
(specifically one complexed with the CD8 molecule, typically found on cytotoxic T 
cells). 
The immune response associated (alternatively designated as Ia (2) or Ir (3» gene 
family is synonymous with the H-2 class II set of genes. These genes are located in the I 
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region of the H-2 complex of the MHC, which consists of subregions A and E (as well as 
B, J, and C, which are probably mapping artifacts). These code for the MHC class IT 
molecules, which, like the MHC-IA molecules, exhibit extreme polymorphism in the 
peptide binding domains of their encoded proteins. The I-A subregion codes for the a 
and ~ chains of the I-A functional protein as we]] as the highly polymorphic ~ chain of 
the I-E MHC-II, whereas the I-E subregion codes only for the less polymorphic a chain 
of the I-E MHC-II. The general shape of MHC-I and MHC-IJ molecules is the same, 
except that MHC-II molecules do not use the ~2 microglobulin protein, and they are more 
open at the ends of the peptide binding groove, allowing greater heterogeneity of peptide 
lengths. Instead, both chains (a and ~) are about the same size and are roughly 
symmetrical. Together they form a functional MHC-II protein, which presents a 
processed peptide to a T cell receptor (specifically one complexed with the CD4 
molecule, typically found on helper T cells). Hence, an I-A gene is for a class II protein 
and should not be confused with an MHC-IA gene. Whether mixed haplotype 
heterodimers occur (e.g., H-2Ao.kE~k; see below) is controversial (3), 
Inbred mice have been used to. study the MHC. By inbreeding it is possible to 
establish a nearly uniform genetic background for a given inbred strain (e.g., B 10), and 
by crossing such inbred strains with repeated backcrossing with a parental strain and 
selecting for recombinants of interest it is possible to establish con genic strains, such that 
they have the region of interest (e.g., the MHC) of one parental strain on a genetic 
background of the backcrossed parental strain. Such mice are designated as, e.g., B lO.A, 
where BID is the background strain and A is the donor strain (2). (Further appropriate 
breeding can give homozygous recombinant con genic strains, which differ from the 
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parental strains by just a few genes in the MHC.) A haplotype is the set of a11e1es found 
at two or more genetic loci on a single chromosome in a given individual (4). Because 
responsiveness to T cell epitopes is determined by the MHC haplotype of the animal, the 
proper choice of haplotype is critical to the success of a study involving T cell epitopes. 
H-2 haplotypes in inbred mice are arbitrarily designated by letter superscripts, so that an 
animal that has the k haplotype is designated as H-2k. Except for my earliest pilot 
studies, all of the animal studies described in this dissertation use B 10.A mice (H-2a 
haplotype on a b background). These mice are a con genic strain derived from AlWySn 
as the H-2 donor and B IO as the background (2); the A strain (either AlWySn or AlJ*-) 
was derived from (k x d) FI mice, with recombination occurring between the E and S 
regions of the H-2 complex (3). Hence, BI0.A mice are of the H-2a haplotype, but this 
haplotype shares the same I-A and I-Ealleles as other strains also derived from the H-2k 
haplotype, namely I-A k and I_Ek. Note that individual loci retain the designation of the 
founder strains, so that the full catalog description of the loci for the H-2a haplotype is 
to a commonly used haplotype, whereas the K region of the H-2 codes for MHC-I K 
antigens, so that I-A k and I_Ek molecules are both MHC-II polypeptides (ex. and B chains) 
encoded by a mouse possessing k alleles at these loci. 
Types of epitopes 
For B cells the principal biomolecule is an antibody, which can exist in one of 
several antibody classes and can be membrane bound or secreted. Regardless of class, an 
:I: The fWySn or IJ suffix simply means that this breed has been maintained for at least 20 
generations at the particular breeding facility. Such mice are in principle the same but 
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antibody consists of a homodimer of heterodimers: there are two light chains and two 
heavy chains. (The class is determined by the heavy chain.) Both the light and the heavy 
chains have constant regions that are encoded by germline genes and also variable 
regions that are encoded by genes resulting from combinatorial shuffling of a set of 
germline genes with a specific recombinase. Within the variable region there are regions 
of lesser variability from one antibody molecule to another that are known as framework 
regions, and also other regions that show extreme variability, known as hypervariable 
regions. It is these hypervariable regions that in1part antigenic specificity, and they are 
consequently also known as conlplementarity determining regions (CDRs). For T cells 
the principal biomolecule is the T cell receptor (TCR), and the T cell epitopes that it 
recognizes are linear peptide fragments displayed in the groove of an MHC-I or II 
molecule. TCRs are heterodimers of two roughly equaJIy sized polypeptide chains, an ex. 
chain and a ~ chain, or else a y chain and a .5 chain. (y.5-TCRs are less common and 
much less understood than are ex.~-TCRs.) As with antibodies, TCRs also possess CDRs, 
three on the ex. chain and three on the ~ chain. Most CDRs of antibodies and probably 
also of TCRs fall into certain classes or famiJies; however the third CDR of the heavy 
chain (and the third CDR of the ~ chain) does not fall into a particular class, being the 
result of V -D-J gene reanangements (6). Consequently the CDR-H3 exhibits the most 
variability of antibody CDRs and plays a key role in antigen binding (7). 
As mentioned above, epitopes are the regions of antigens that are recognized by 
immune biomolecules. For antibodies these epitopes can be regions of an antigen that are 
spatially near each other and can be either contiguous or noncontiguous in the amino acid 
could have evolved slight differences. 
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sequence of a protein antigen, for example. Hence, the B cell clonal population 
recognizes molecular shape and uses that to distinguish self antigens from foreign 
antigens. § T ce]]s, in contrast, distinguish self from non-self by recognizing genetic 
information in the form of a peptide fragment that has generally been derived from either 
a self or a foreign protein. Such peptides are T cell epitopes. For most vaccines it is 
important to get a T cell dependent response, which requires the use of suitable T cell 
epitopes either as individual peptides or still incorporated into the parent protein. 
T cell epitope mimicry 
Although peptides have been used as immunogens for two decades, most of these 
studies have examined their use as B cell epitopes, i.e., can a polyclonal anti-peptide 
antibody response crossreact with the parent protein? Undoubtedly part of the reason for 
this is historical; antibodies were discovered many decades before TCRs and are easier to 
assay. Hence, the first studies involving peptides as epitopes used them as haptens 
coupled to a carrier protein. Later, in 1988 James Tam found that peptide epitopes could 
be joined together into a branched oligomer, known as a multiple antigenic peptide 
(MAP), and that one could dispense with carrier proteins using such a construct (10). 
Also in the late 1980s it became clear that T cell epitopes were different in their nature 
from B cell epitopes; they were always contiguous and were not affected by protein 
denaturation. Consequently in the early 1990s various investigators examined MAPs 
(reviewed in (11)) and compared them to the classical carrier protein approach and to 
monomeric peptides. For the most part MAPs were found to be superior to monomeric 
§ Self vs. nonself discrimination is a' widely used terminology in the immunological 
literature but is not without some debate (8, 9). While I acknowledge the existence of this 
debate, I will not join it and will use this terminology as a convenience. 
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peptides and comparable to carrier proteins. These studies in which MAPs were 
compared against carrier proteins generally used keyhole limpet hemocyanin or some 
other foreign protein widely used in immunological studies, since that was what had been 
done in the past in generating anti-peptide antibodies and the authors of those studies 
were concerned with comparing the new technology against the traditional procedure. 
However, those comparisons were all somewhat unfair, "apples to oranges" comparisons 
since the T cell epitopes used in the MAPs were not from the same antigen as the carrier 
protein. Consequently we decided to investigate explicitly how well an immunodominant 
T cell epitope can replace its parent carrier protein in telms of generating a strong, T cell 
dependent antibody response. These studies comprise Chapters 3 and 4 of this 
dissertation. 
B cell epitope mimicry 
Although the immune system is designed for protecting against disease, it too can 
be pathological. Immune system pathologies include infections, cancers, insufficient 
immunity, and autoimmunity. In autoimmune diseases and in lymphocyte cancers it 
would obviously be advantageous to specifically target cytotoxicity to the clones 
responsible for the pathology. Such targeting requires that there be molecular differences 
that set the pathological clones apart from healthy cells. 
Idiotopes are defined serologically as the epitopes on the variable regions of 
antibodies that are recognized by other, anti-idiotope antibodies (12). The complete set 
of idiotopes on a given antibody constitutes the idiotype (Id) for that antibody. Because 
they are unique to a given clone, idiotypes are ideal targets for those cases in which a 
particular clone is undesirable, such as in multiple myeloma, non-Hodgkin lymphomas, 
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leukemia, and certain autoimmune diseases. For a peptide vaccine to function as a B cell 
epitope mimic it is essential that there be crossreactivity with the parent protein, in this 
case the antibody that defines the pathological clone. Hence, our B cell epitope mimic 
was also an idiotope mimic. 
The advantage of using idiotypes as targets is also their disadvantage: because 
they are unique, therapies need to be customized to each patient. Various groups have 
investigated the use of anti-idiotype antibodies in humans and in mice as a means for 
targeting a given clone for over two decades (13-17). These approaches can be divided 
into dichotomous categories: either one could generate anti-Id molecules (usually 
antibodies) from outside the patient and then treat the patient with such anti-Id molecules, 
or else one could vaccinate the patient using the patient's Id but in a form which will 
stimulate the immune system to mount a response against it. Both approaches seem to be 
effective, but because more is now known about immunology in general and because the 
latter, patient vaccine approach has the very significant advantage of not requiring 
antibody purification, the latter approach is now more popular. Within the patient 
vaccine approach, several approaches can be taken. Ideally one would like to simply use 
cDNA made from a tissue biopsy and not deal with protein purification at all. This is 
possible with peptide mimics of the major idiotopes (13, 18-24) and, more recently, with 
DNA vaccines (25-27). 
The initial goal for the B cell mimicry aspects of this dissertation was to generate 
anti-idiotype antibodies against a murine model antibody. Specifically, we were 
interested in examining quantitatively the question of how well a cyclic peptide mimic of 
the heavy chain's CDR-H3 could replace the parent protein, i.e., how well an idiotope 
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mimic can replace an entire idiotype in tenus of an anti-idiotype antibody response, 
thereby extending an earlier study in the literature (22). 
Specific aims 
As noted above, we hypothesized that the immunodominant T cell epitope from a 
commonly used carner protein could effectively replace the use of the intact parent 
protein in tenus of generating a T cell dependent response. We also hypothesized that a 
peptide mimic of a key idiotope, based on the third CDR of the heavy chain, would be a 
suitable antigen for generating crossreactive antisera. To test these hypotheses we set out 
to accomplish the following specific aims: 
1. To use molecular graphics as an aid to picking the best sequence for use as a 
helper T cell epitope in B10.A mice. In particular, we wanted to know which 
residues from the p46-61 tryptic digest peptide played key roles in binding to 
the MHC-II (l-Ek) and to use this knowledge to extend or shorten the peptide 
as appropriate. 
2. To use molecular graphics to design a peptide mimic of the CDR-H3 of a 
model antibody, BV04-01. 
3. To use molecular modeling to evaluate the dynamics of an intact idiotype 
under two different solvation treatments: generalized Born implicit solvation 
and particle mesh Ewald explicit solvation. 
4. To directly compare the potency of a peptide based on the immunodominant T 
cell epitope of a canier protein with the intact carrier protein itself in tenns of 
generating a strong T cell dependent response in vivo. 
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5. To use a peptide D1imic based on the CDR-H3 of a model antibody, together 
with a carrier protein or a peptide based on the immunodon1inant T cell 
epitope of such a carrier protein, as an antigen against which crossreactive 
antibodies were to be generated, and to directly compare the crossreactivity of 
the antisera of mice immunized with the peptide mimic (the idiotope) with the 
antisera of mice immunized with the idiotype (similarly derivatized so as to 
make it foreign to the mouse immune system). 
The first two specific aims are described in Chapter 2. As noted in Specific Aim 
2, the antibody initiaJJy chosen for the purpose of evaluating idiotope mimicry was 
BV04-01, an IgG2b (K Jight chain) derived from a murine model of systemic lupus 
erythematosus. This antibody proved to be difficult to work with, so later I changed the 
Id protein to be the Fab' fragment of 9-40, an anti-fluorescein murine IgG 1. This is the 
focus of Specific Aim 5, and the results of that study are given in Chapter 5 of this 
dissertation. 
Chapter 6 deals with Specific Aim 6 - how wel1 one can model the structure of an 
Fv fragment, that is, the variable portion of a Fab fragment of an antibody. This builds 
upon similar work in Chapter 2. The scope of this modeling is strictly structural; it is to 
improve upon homology models by taking time averaged structures as a model for the 
solution structure of an antibody. I hope to publish this work along with ongoing and 
future work involving Ab-Ag binding free energies, but those studies are beyond the 
scope of this dissertation. Specific Aim 4 is the subject of Chapters 3-4. 
Finally, Chapter 7 is a discussion of the conclusions of this dissertation as a whole 
and suggestions for future work. Because Chapters 3-4 have been submitted for 
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publication and Chapters 5-6 are intended to be submitted for publication, they are 
written as complete units with conclusions germane to those chapters. Consequently 
much of the future work mentioned in Chapter 7 pertains to further molecular modeling 
computational experiments. 
CHAPTER 2 
STUDIES \VITH BV04-01 AS MODEL SYSTEM 
This chapter discusses the original molecular modeling work on the CDR-H3 loop 
of anti-ssDNA antibody BV04-01, as well as the rationale and results for some of the wet 
lab work involving this antibody. Not all of the synthetic experiments are described since 
that would involve much discussion and details of a model system (BV04-01) which was 
eventua))y abandoned anyway. Nevertheless, the work with BV04-01 did provide the 
rationale for all the subsequent work, and there were some interesting experiments 
performed which I would like to describe. 
Abstract 
Initial molecular modeling studies: MD and MM simulations 
of a series of CDR .. H3 peptide mimics 
Molecular dynamics (MD) simulations were performed on a series of cyclized 
peptide mimics of the third hypervariable region of the heavy chain (CDR-H3) of 
monoclonal Ab B V04-0 1, with the conformation of the peptide in the trajectory saved as 
molecular snapshots at 1 ps intervals. The initial conformations of these peptide mimics 
(CDQTGTA WFAC, CNQTGTA WFAC, and CQTGTAWC) were based on the Jiganded 
and the unliganded crystal structures of the Fab fragment of BV04-01. The simulations 
were performed on the peptides in the disulfide-bonded, cyclized state, conjugated to a 
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Lys via the crosslinker disuccinimidylglutarate, with the Lys atoms constrained and the 
crosslinker atoms restrained with a tethering function as an approximation to a carrier 
protein. AU systems were hydrated and simulated using periodic boundary conditions. A 
30 ps dynamics run was performed with snapshots taken at 1 ps intervals. These were 
minimized and compared against each other and against the native crystal structure of the 
CDR-H3. Modeling results indicate that within the time frame examined each set of 
conformers shows rms deviations from each other and from the initial starting structures 
that are within typical resolutions found by X-ray crystallography and roughly within a 
factor of 2 of the rms deviations of the liganded and unliganded structures in the first 
place. Hence, it appears that conformational variabi1ilty of these peptides is low enough 
for them to serve as acceptable mimics for use in vaccines, although a longer simulation 
time would have been better. 
Background and purpose 
Central to the antigenicity of a peptide is the shape that it presents to the immune 
system. As discussed in Chapter 1 and later in Chapter 5, the best idiotope for a peptide 
mimic is the CDR-H3. Some early studies using a linear peptide mimic of this region 
were unsuccessful, however (Prof. David M. Kranz, University of Illinois at Urbana-
Champaign, personal communication). One possibility for this result is that the peptide 
exhibited too much conformational flexibility, so that the immune system did not 
encounter a single antigenic hapten. We hypothesized that a cyclic version of such a 
peptide might instead be a better nlimic, and desired to study the conformational mobility 
of the peptide to see how it relates to the conformation in the parent antibody. The goal 
of this initial study was to get some measure of how well such peptides should mimic the 
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original BV04-01 CDR-H3. The expectation was that a disulfide bridge would limit the 
set of confonners that would be presented to the immune system when using these 
peptide mimics as B cell epitopes in vaccines. 
The antibody chosen for this purpose was BV04-01, an autoantibody (against 
ssdT) derived from a murine model of systemic lupus erythematosus. Besides being an 
autoantibody, for which we hoped that it could serve as a proof of principle for anti-
idiotype targeting in the context of an autoimmune disease, BV04-01 has another 
important advantage: the crystal structures of both the liganded (with dT3) and the 
unliganded Fab fragments are available (28). Our initial goals in molecular modeling 
were (1) to use molecular graphics as an aid to picking the most appropriate peptide 
mimics, and (2) to use molecular dynamics as an aid to understanding the similarity of 
the peptide mimic to the actual CDR-H3 loop. 
The CDR-H3 of BV04-01 is a hairpin loop. This loop is mostly solvent exposed; 
however, the C-terminal residue in this region (Tyr HIIO by strict numbering or Tyr 
HI02 by the Kabat numbering scheme (29)) is not well exposed. This residue was 
replaced by Cys in our peptide mimic. An N-terminal Cys was also added in order to 
allow cyclization through disulfide formation. Thus, this constituted one of our peptide 
mimics (CDQTGTAWFAC). 
The molecular graphics provided insight into two other reasonable peptide 
mimics. In the crystal structure the D in the CDR-H3 (Asp H95, Kabat numbering) 
makes a salt bridge with Arg H50, which would partial1y neutralize the charge density 
around H95. This suggests that a D -7 N mutation might work as well or better as the 
original sequence, and also has the significant synthetic advantage that there is only one 
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carboxylic acid group through which attachment of the peptide mimic via standard 
carbodiimide chemistry could occur. In that case there is no possibility of coupJing 
through the Asp side chain. Since we ultimately desired to synthesize these mimics and 
incorporate them as actual immunogens, we considered this sequence as wel1. Fina1ly, 
based on the computer graphics display we could see that cyc1ization through a shorter 
peptide could still encompass the most accessible residues of the CDR-H3, so we 
designed a third peptide mimic, CQTGT A WC. 
Methodology 
We used a Silicon Graphics Iris Indigo XS24 4000 to run the molecular graphics 
program lnsightll (formerly BIOSYM Software, now Accelrys) Version 2.3.5 as an aid 
to chosing which amino acids to include. MD is sensitive to the starting conditions, and 
the most reasonable starting conditions are the liganded and unliganded crystal structures 
(lCBV and INBV respectively in the Protein Data Bank) for each of the three sequences, 
gi ving six simulations. The nonrelevant residues were deleted. The flanking residues 
(e.g., 100H and 110H) were changed to cysteines and then disulfide bonded. The 
resulting cystine was minimized to a 0.001 maximum rms derivative using conjugate 
gradients and the default consistent valence force field (CVFF) while keeping the other 
atoms fixed to preserve the native structure of the peptide using the software Discover 
Version 94.0 (BiosymlAccelrys). Then a minimized homobifunctional crosslinker, 
disuccinimidyl glutarate (DSG), was attached to the N terminus, and a Lys was attached 
to the other carbonyl of the DSG. This was again minimized, again keeping the peptide 
fixed (except for the Cys residues). Then the molecule was hydrated and put in a box 
with space group 3 symmetry. Minimum image periodic boundary conditions were 
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applied. Each box had at least 3 A on each side of the molecule to allow sufficient 
hydration. Because the molecules folded up into different conformations in vacuum (and 
also one of the peptides is smaller than the others), the boxes for the six simulations were 
not a]] the same size and shape. Since the waters add most of the computational burden, 
this sharply cut down the computer time required for simulating the smaller and more 
compact molecules. 
The hydrated molecule was then relaxed to a 0.05 maximum rms derivative, this 
time allowing the peptide and part of the DSG to freely relax while the Lys was fixed. 
This was done because the peptides had been synthesized and crosslinked with a large 
carrier protein (keyhole limpet hemocyanin, KLH) by means of disuccinimidylglutarate 
(DSG), which forms amide bonds between the N terminus of the peptide and Lys side 
chains of the carrier protein. Since it was computationally impractical to try to include 
the structure of KLH in the simulations, the fixed Lys was intended as a simplistic 
approximation. The DSG carbonyl closest to the Lys had a force constant of 100 kcallA, 
the methylene group after this had a force constant of 50 kcallA, and the one after this 
had a force constant of 25 kcallA. Finally, a dynamics run was initialized and performed 
for 30 ps simulation time at a temperature of 310.15 K using the default constant volume, 
constant density ensemble, with snapshots of the system taken at 1 ps intervals. These 
were minimized (again using CG and CVFF but to a 0.05 rms derivative) and compared 
against each other and against the starting Jiganded and unliganded CDR-H3s. 
Results 
All of the peptides show a jagged appearance in graphs of total energy vs. frame 
(i.e., minimized conformer). Also, the cluster graphs show approximate families of 
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confonners, which tend to correspond with the energy vs. frame graphs. Cluster graphs 
show the nns deviation of a given frame versus every other frame in that simulation (i.e., 
versus every minimized snapshot) by assigning ranges of nns deviations to different 
colors. (They are actually three dimensional plots with the z axis perpendicular to the 
viewer.) Frames of low nns deviation mayor may not be separated by clusters of higher 
nns deviation. Some of the total energy vs. frame plots show a general decrease in time 
(i.e., frame), indicative of a presently relaxing system. This implies that the starting 
condition was still exerting an artifactual effect, so that 30 ps was insufficient for 
achieving good sampling of the low-energy conformers. Maximum rms deviations of 
conformers (i.e., the highest color-coded cluster in the cluster graphs) is shown in Table 
l. A typical energy and cluster graph pair (for the first entry in Table 1.) is shown in 
Figure 2. For comparison, a 1.169994 A rms difference is found between the initial apo 
and holo fonns of the peptide CDQTGTAWFAC (i.e., the unliganded and Jiganded CDR-
H3 loops but with flanking cysteines). 
Conclusions 
The energy vs. frame plots show qualitative agreement between total energy and 
confonners with little nns difference from each other. The rms differences between the 
minimized confonners are within typical values for resolutions found by X-ray 
crystallography and roughly within a factor of two of the rms differences between the 
initial, native apo and holo structures. (The 1 CBV structure was solved to 2.66 A and the 
INBV structure to 2.00 A.) The present results show the extent to which a typical, small, 
disulfide-linked peptide can vary in its conformations. The linlit for which good 
antigenicity can be attained has not been deternlined in the present study. Other than the 
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Table 1. Early MD results. 
Peptide and initial conformer Rms deviation, A Comments 
CDQTGTAWFAC apo 1.80 possibly insufficient time, 1st frame 
is second highest in energy 
CDQTGT A WF AC holo 2.57 ibid. 
CNQTGTAWFAC apo 2.40 likely sufficient time, 1st frame IS 
highest in energy 
CNQTGTAWFAC holo 2.57 possibly sufficient time, 1 st frame is 
highest in energy 
CQTGT A WC apo 2.14 likely insufficient time, 1st frame is 
highest in energy 
CQTGT A WC holo 2.14 possibly sufficient time, 1 st frame is 
highest in energy 
Figure 2 Sample energy versus time and cluster graph for one of the six simulations 
listed in Table 1. 
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native holo and apo crystal structures, which were used as starting structures, none of the 
other, computed conformers are of special interest in themselves. 
It is apparent that the simulation time was insufficient to adequately sample a 
representative number of low energy solvated conformers, with maybe one exception. 
Hence, somewhat more time, perhaps 100 ps, would have probably been demonstrative 
of an absence of a strong initial conformer effect. A complete study of the conformations 
which the present peptides could attain would require far more computer time than that 
used in this study. 
Pilot studies with peptides coupled to KLH 
Synthesis and imnlunization methodology 
Each of the above three peptides were synthesized at the University of Utah's 
Peptide Facility (now the PeptidelDNA Facility) by standard Fmoc solid phase peptide 
synthesis, purified by HPLC, cyclized by air oxidation of the disulfides, and analyzed by 
MALDI-MS. Each was then coupled to the commonly used carrier protein keyhole 
limpet hemocyanin (KLH) via the homobifunctional crosslinker disuccinimidylglutarate 
(DSG; Pierce Chemical Co.) after the manner of the DSG instructions provided with the 
product. FemaJe BALB/c mice were immunized intrapelitoneally or subcutaneously with 
these immunogens in Hunter's adjuvant (1st, 2nd, and 3rd injections) or Freund's 
incomplete adjuvant (subsequent immunizations). Bleedings were performed approx-
imately 2 weeks later. 
ELISA results 
Titers were measured by a sandwich ELISA with the coating antigen being either 
BV04-01 Fab or one of the peptides coupled to another protein (bovine serum albumin, 
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BSA). Many of the ELISAs exhibited an edge effect in which the outside edges were 
more strongly positive than they would be expected to be. This phenomenon necessitated 
considerable optimization and control reactions. Hence, the assay was sensitive but 
imprecise. Titer was defined as the maximum diJution at which a positive response could 
be distinguished from the background or negative control for an arbitrary confidence 
level by a many-one t test such as the Bonferroni t test or Dunnett's test. Mice were 
ranked based on both their absolute response to BV04-01 Fab and their preferential 
response to BV04-01 Fab relative to 9-40 Fab. Hence, the product of these two quantities 
was used to rank the mice (Figure 3). 
Conclusions 
From Figure 3 it can be seen that of 9 surviving mice (out of 15 originally) only 
one (mouse 1-0) showed a good anti-idiotype response. Two showed a mediocre 
response, and the others showed no specific anti-(BV04-01 Fab) response. Monoclonal 
antibody production was attempted but these attempts were unsuccessful for various 
Pilot study mice, ranked based on (8V04-01 titer)2/(9-40 titer) 
100000 
II BV, 1st 
- 10000 • BV, 2nd ~ 
.s 
E 09-40, 1st 




1-0 3-cs 2-0 3-L 3-0 2-R 1-R 3-R 2-B 
Mouse 
Figure 3. ELISA ranking of initial pilot study lllice. 
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reasons. Although these studies had originally been intended as the stepping stone for a 
discovery-oriented dissertation project that made pharmaceutical use of anti-idiotype 
antibodies (as opposed to a more hypothesis-driven project), they had to be regarded as 
pilot studies only. However, they did offer data that could be used for power 
calculations. 
Why was the response so low? Because KLH is a huge protein (ca. 100 kDa in its 
monomeric form, and it oligomerizes), it was very difficult to see how much peptide 
actually got conjugated. Light scattering was attempted but not useful. Since all the 
mice eventually died with no monoclonal antibodies, and since KLH has the analytical 
difficulties that it does, I decided to start over with another protein, chicken hen egg 
lysozyme (HEL). HEL is a model protein that has been extensively studied both 
chemically and immunologically, as wen as being small, inexpensive, possessing 6 lysine 
residues through which coupling could occur, and possessing an immunodominant T cell 
epitope that lacks Lys or Cys (important so that the T cell epitope would not be disrupted 
by coupling to it B cell epitopes, i.e., peptide mimics of the CDR-H3 loop), and that is 
immunodominant in several mouse strains, including BlO.A (and likely related strains 
with the same I-E and I-A alleles). 
Qualitative nlodeling with H_2k I-E molecule 
The crystal structure of the I-Ek molecule was solved by Daved Fremont and 
others (30). Dr. Fremont kindly supplied me the coordinates prior to releasing the final 
copy to the Protein Data Bank. They were used in conjunction with InsightII and the 
reference article to determine that the most important residues in the peptide 
NTDGSTDYGILQ!NSR (p46-6l, the immunodominant T cell epitope of HEL in BlO.A 
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mice and likely other strains also possessing I-A k and I_Ek molecules) were the ones 
shown above underlined in bold font. The C tenninal R fits into the narrow hydrophobic 
pocket at P9, making a salt blidge with I-Ek's GluB9. Among the peptides that are known 
to bind to murine I-E\ this pocket has a strong preference for R or K (30). The pockets 
P6 and P4 are fairly accommodating to many residues and can accommodate the J and the 
L respectively. PI is a medium sized hydrophobic pocket that can accommodate the Y. 
This simple modeling gave a better feeling for which residues would be indispensable in 
picking the exact sequence for the T cell epitope peptide. 
Use of BV04-01 as model idiotype 
J{ationaJe and design considerations in synthesizing 
idiotype-HEL conjugates 
In order to compare the T cell epitope with HEL itself, we desired to have both 
the construct (Bep-Tep)4-MAP, compared with the Bep-HEL, as well as the idiotype (Id) 
protein Id-HEL, compared with Jd-(Tep), where the Id can be either the entire antibody or 
a fragment thereof that still retains at least the Fv portion. Because the Id and HEL are 
both proteins with primary amine groups present, it would be possible to use amine 
reactive crosslinkers to couple them to each other. That approach has the disadvantages 
of (1) difficult or potentially intractable work-up due to HEL-HEL coupling, Id-Id 
coupling, and higher order crosslinkings if done at high protein concentrations, (2) long 
reaction times and low yields due to crosslinker hydrolysis if done at low protein 
concentrations, and (3) diminished antigen binding activity due to HEL coupling near the 
antigen binding site and providing steric hindrance. Using a Fab' fragment would be the 
optimal choice because (1) it would allow amine and sulfhydryl heterobifunctional 
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crosslinkers to be used in a two-step synthesis, resu1ting in higher yields and no Id-Id nor 
HEL-HEL crosslinking, (2) it would couple the HEL away from the antigen binding site, 
and (3) it would be relatively easy to analyze by PAGE or MALDI-MS due to the 
molecular weights involved. The difficulty with that approach is that BV04-01 is an 
IgG2b, which, unlike other antibody classes, does not readily yield F(ab')z fragments 
with pepsin digestion. A third approach is possible because IgG has carbohydrate 
moieties that can be converted to aldehydes, allowing heterobifunctional crosslinking of 
the HEL with the carbohydrate (31). That approach has the additional advantage of 
coupling HEL away from the antigen binding site but the minor disadvantage of most 
likely generating anti-Fc antibodies. It also turned out to be difficult to analyze. 
Overview of synthetic attempts 
Each of the above strategies was pursued, but the first gave mixtures that were 
difficult to analyze with our available equipment. The second strategy, namely using 
Fab' fragments instead of intact antibody, was attempted with lysyl endopeptidase, which 
has been shown to achieve satisfactory yield with IgG2a antibodies (32). Some Fab' 
product was made with the IgG2b antibody BV04-01, but the yield was low and this was 
deemed not likely to be cost effective. Consequently the most attention was put on the 
third strategy, i.e., coupling through the carbohydrate moieties. 
The initial approach was to use the amine and sulfhydryl reactive heterobifunc-
tiona] crosslinker SPDP (Figure 4) to prepare SPDP-HEL, i.e., with HEL with the Lys 
side chains extended and ending with maleimides. The pyrridyl disulfide group of the 
SPDP was then removed with DTT to generate 2-pyrridylthione and HS-HEL. The Ig 
was oxidized with NaI04 to convert the terminal carbohydrate moieties to aldehydes, and 
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Figure 4. Structures of SPDP and some hydrazide containing crosslinkers mentioned in 
this dissertation (available from Pierce Biotechnology, Inc., Rockford, IL). 
then reacted with MPBH to have maleimides attached to the Fc region. Finally, the HS-
HEL was mixed with the MPBH-IgG. This reaction failed, however, and thus began 
dozens of diagnostic and alternative conjugation experiments. 
The first step with the antibody, oxidation with NaI04, proceeded well. This is 
shown most clearly in the kinetics of this reaction (see Appendix A). The resulting 
hydrazone bond is unstable (again, see Appendix A for details). Other crosslinkers were 
also tried: KMUH, PDPH, ABH (Figure 4), as well as a couple that were not available 
commercially (described in Appendix A), as well as simply letting the HEL in high 
concentration form an imine linkage with the Igox. Such linkages were tried both with 
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and without reduction of the imine with NaCNBHt. Some couplings proceeded with at 
least partial success (e.g., with ABH), but it was difficult then to quantify the 
stoichiometry of the conjugate. Both Western blotting and ELISA can be quantitative 
with appropriate standards, which were lackjng, but also which apparently suffered from 
a surprising crossreacti vity between our polyc1onal goat anti-(mouse IgG), HRP 
conjugate and BEL itself. Mass spectrometry should show such conjugation easily in 
principle, but in fact MALDI itself seemed to break the linkage between the Ig and the 
BEL. 
Conclusion of BV04-01 as idiotype of interest 
Although the IgG-BEL conjugate was made in some yield by various techniques, 
it was very difficult to quantify the yield. Since the B epitope hypothesis (idiotope vs. 
idiotype mimicry) could be tested by a Fab' -BEL coupling, without requiring MAPs (so 
that the use of zero-1ength crosslinkers to maintain similarity of coupling between the B 
epitope and the MAP as with the B epitope and the carrier protein is not an issue), and 
since the T cel1 epitope hypothesis could be tested without requiring Id-HEL coupling (or 
MAPs), we felt that it was better to switch to the Id of another antibody which could be 
made readily into Fab' fragments. For this purpose we chose 9-40, an IgGl for which the 
optimization of Fab' fragment preparation had already been worked out in our laboratory. 
The disadvantages of switching were (l) that 9-40 is not an autoantibody, unlike BV04-
01, so the immediate relevance to lupus and other autoimmune diseases is lost, and (2) 
my modeling work had been done with the CDR-H3 of BV04-01. However, the first 
disadvantage is trivial because this is only a model system to test specific hypotheses and 
no clinical relevance in lupus-prone mice to BV04-01 itself has been shown, nor was that 
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in the scope of my project. The second disadvantage was likewise very weak since it 
would be desirable to do longer, more extensive computational experiments that were 




lIO'V \VELL CAN A T CELL EPITOPE REPLACE ITS PARENT 
CAHHIEH PROTEIN? PART 1: AN ANOVA STUDY 
Abstract 
Peptide vaCClnes require T cell stimulating epitopes in order to generate an 
effective T cell dependent response. The goal of this study was to see how well an 
immunodominant T cell epitope can replace its parent protein in tenns of generating an 
antibody response. 
Methods 
The immunodominant T cell epitope (modified by replacing Cys-64 with Ser, 
thus: GSTDYGILQINSRWWSND) for BIO.A mice (H-2a) from chicken hen egg 
lysozyme (HEL) was synthesized and conjugated to the Fab' fragment of anti-fluorescein 
monoclonal antibody 9-40 using SMCC as a heterobifunctional linker. Similarly, the 9-
40 Fab' fragment was coupled to the intact HEL molecule. Both sets of constructs were 
injected subcutaneously into B 10.A mice. Control mice were immunized with 9-40 or 
with a noncova]ently attached mixture of 9-40 and HEL on a roughly equimolar basis. 
ELISA was used to measure titers of specific anti-idiotype antibodies directed towards 
the 9-40 idiotype. 
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Results 
Anti-idiotype antibodies were raised against 9-40 using the (9-40)Fab-HEL 
conjugate, but not for the control cohorts nor for the (9-40)Fab-(T epitope) conjugate (p = 
4.89 x 10-13). These antibodies were crossreactive with idiotypically related clone 4-4-
20 but not with ELISA controls BV04-01 nor BDCl. 
Conclusions 
A monomeric immunodominant T cell epitope conjugated to an immunologically 
silent protein is unlikely to provide an effective T cell dependent response. This result 
poses a challenge for the development of efficacious peptide vaccines and is explored 
more fully in Part 2 of this study (Chapter 4), dealing with the dose response functions of 
this epi tope. 
Introduction 
Next to sanitation, vaccines are the most cost-effective means to improving public 
health. Early vaccines used live attenuated or heat-killed organisms for their success, but 
this approach is not suitable for widespread use for cases in which the organism cannot 
be easily grown in culture (e.g., malarial and schistosomal parasites). In these cases 
subunit vaccines are especially promising. Cancer vaccines are also particularly 
amenable to the subunit approach, since simply formulating killed cancer cells as a 
vaccine could potentially elicit immune responses against antigens that are not cancer 
specific. Subunit vaccines could be based on either entire proteins through molecular 
biology techniques, or simpler peptides that incorporate the epitopes recognized by T 
cells and by B cells, depending on the desired type of response (cytotoxic or humoral, for 
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example). Peptide vaCCInes In particular offer the advantage of not including those 
regions of a protein or virus not involved in immunity. The main difficulty with peptide 
vaccines is the need to overcome genetic restliction by extremely diverse HLA (MHC) 
haplotypes. Immunological understanding in the 1970s and '80s held that peptides and 
other haptens are not inlmunogenic unless coupled to a foreign carner protein and that the 
size of the carrier protein somehow imparts imnlunogenicity. This idea still finds its way 
into the introductions of research articles and the technical support pieces of product 
vendor literature, but it is not size as such that imparts immunogenicity. Rather, foreign 
proteins possess within their primary sequence regions that are processed and then 
displayed in the binding groove of an MHC molecule, thereby alerting T cells that they 
have been deri ved from a foreign source (33). These T cell epitopes are linear peptides 
enzymatically derived from a protein and play an important role in the activation, 
tolerization, or ignorance of the immune system, and consequently much work has been 
done to elucidate the T cell epitopes for a nUITlber of proteins associated with various 
pathogens as well as in autoimmune diseases. 
Once such T cell epitopes are identified, they can then be used as part of a vaccine 
formulation to acti vate cytotoxic T cells or to provide T cell help in the response against a 
separate B celJ epitope. This has been done repeatedly in the case of multiple antigenic 
peptides (reviewed in (11, 34)), in liposomes (35-38), as tandem oligomeric repeats or 
linear peptides (39, 40), and as pendant groups from a polymeric backbone (41). Most 
such studies involve rodents with well-defined MHC haplotypes, but as noted above, 
individual T cell epitopes pose problems for consideration as vaccines in outbred 
populations such as humans. This difficulty is complicated by the fact that there are 
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dominant, subdominant, and cryptic T cell epitopes within a typical protein (reviewed in 
(42)). Fortunately there exist so-called promiscuous T cell epitopes which are recognized 
by a wide variety of MHC haplotypes (43). In any case, the question then arises as to 
how well an immunodominant T cell epitope can substitute for its parent carrier protein 
when used as part of a peptide vaccine formulation. To the best of our knowledge, no 
one has specificall y investigated this issue. 
We chose chicken hen egg lysozyme (l-IEL) to answer this question, as this 
protein is small (14.3 kDa), inexpensive, easily soluble, and very well characterized 
chemically and immunologically (44). Because the synthesis of the immunodominant T 
cell epitope would be more convenient if one did not need to bother with disulfide 
formation or side reactions involving crosslinker derivatization of Lys side chains, we 
decided to use the immunodominant T cell epitope in B 10.A mice along with its flanking 
residues (but modified by replacing Cys-64 with Ser, thus: GSTDYGILQINSRWWSND) 
(45). 
The simplest approach to evaluating how well a T cell epitope can replace its 
parent carrier protein would be to conjugate a hapten or an immunologically silent 
protein to either the epitope or the carrier protein and then to compare cohorts of mice for 
the immune response. Because we were also interested in preparing anti-idiotype 
antibodies in a model system with the ultimate goal of targeting pathological B 
lymphocytes for the patient-specific treatment of numerous diseases (such as hairy cell 
leukemia, various non-Hodgkin's lymphomas, multiple myeloma, systemic lupus 
erythematosus, Hashimoto's thyroiditis, insulin-dependent diabetes mellitus, Graves' 
disease, and Addison's disease), we decided to use the Pab' fragment of the murine anti-
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fluorescein antibody 9-40 as the immunologically silent protein. 9-40 is a very well 
characterized murine monoclonal anti-fluorescein IgGl (46, 47) available in our 
laboratory, for which preparation of Fab' fragments has been optimized. It is a good 
choice for anti-idiotype studies because its idiotype has been well studied (48); it is a 
member of a family of idiot ypic all y crossreactive antibodies (49-51), including high-
affinity antibody 4-4-20, for which the crystal structure of the liganded Fab fragment has 
been solved (52). A potentia1 difficulty with 9-40 would be that it is derived from a 
different strain of mice than BI0.A (specifical1y, BALB/c), so that there is the potential 
for an anti-a]]otype response that could be difficult to distinguish from an anti-idiotype 
response. However, because we used only the Fab' fragments in our immunogens 
instead of derivatizing the intact antibody with HEL (for example, through the 
carbohydrate moieties (31)), the epitopes responsible for an anti-allotype response are 
largely missing, and so this potential concern should not be too problematic. Our results 
fulIy support this supposition. 
1\1aterials and methods 
Synthesis of (9-40)Fab' 
The (9-40)F(ab')2 was prepared by the method of Grey and Kunkel (53). In brief, 
the 9-40 IgG was digested by pepsin at 37°C for 18 h using 0.1 M acetate buffer (pH 4.2) 
with an enzyme:Ab mass ratio of 1:33 (= 117.56 molar ratio). The reaction was quenched 
by addition of a few drops of 1.0 M Tris base to pH 8.0. The reaction mixture was then 
concentrated after SEC (PD-I0, Amersham) to -1 mglmL; 1 mL was then used for 
subsequent modification. The resulting (9-40)F(ab')2 was then cleaved in the same 
reaction vessel with DTT to generate (9-40)Fab'. Specifically, 220 JlL of Tris buffer was 
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added to 1.0 mL of -1 giL (9-40)F(ab')2 solution, vortexed, then 22 JlL of 0.2 M EDT A 
solution (in the same Tris buffer) was added and vortexed. Then 22 JlL of the DIT stock 
solution (0.1 M, freshly prepared in 1 M Tris buffer, pH 7.37) was added, vortexed, and 
then put in the dark at room temperature for 1 h. Meanwhile, a PD-I0 SEC column was 
equilibrated with 0.1 M NaP04, pH 6.0,5 mM EDTA. The protein was then eluted with 
this buffer and appeared after ca. 1.5 - 4.0 mL. The purified (9-40)Fab' was then 
measured by UV spectrophotometry and immediately reacted with the desired 
electrophilic partner. For the (9-40)Fab' negative control this was iodoacetamide. 
Synthesis and analysis of (9-40)Fab'-HEL 
BEL was dissolved in pH 8.0 PBS and then derivatized with a large ( .... IOO-fold) 
excess of SMCC (Pierce) for several hours at room temperature. Excess SMCC was 
removed by SEC and the derivatized BEL was set aside until the (9-40)Fab' was made, at 
which point it was immediately added to the (9-40)Fab' and allowed to react overnight. 
Specifically, 1.2 mL of the freshly prepared (9-40)Fab' solution, 9.22 JlM (E = 47,600 M-
Icm-I), was added to 0.1 mL of 35 JlM SMCC-HEL in pH 7.4 PBS and allowed to react 
overnight at 4°C. The reaction product was analyzed by several different techniques 
including SEC, ELISA, SDS-PAGE, and MALDI-MS. SEC chromatogram fractions 
were assayed for both 9-40 Fab' and HEL by ELISA. Fractions testing positive for both 
were pooled, concentrated, and then characterized by SDS-PAGE. These techniques 
indicated that although the conjugation reaction had been successful, the yield was 
relatively low (20%, or less). The conjugate was not purified further because the 65 kDa 
conjugate could not be resolved from the 50 kDa 9-40 Fab' using SEC. This was not 
deemed a problem, however, because the underivatized antibody fragment was not 
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expected to be immunogenic (a postulate that was later confinned by our control 
experiments). Subsequent preparations of the (9-40)Fab' -HEL were made using the same 
procedures and further validated by MALDI-MS. 
Synthesis and analysis of (9·40)Fab'-(T epitope) 
The T cell epitope GSTDYGILQINSRWWSND was made by batch Fmoc solid 
phase synthesis at a professional peptide synthesis service located on the University of 
Utah campus (the DNA/Peptide Facility) and was analyzed by RP-HPLC. This material 
was then derivatized with SMCC and again analyzed by HPLC (Figure 5). The putative 
product peak was confirmed by MALDI-MS (Figure 6) and then evaporated (Speedvac) 
to a solid. It was later redissolved in DMF and reacted with freshly prepared (9-40)Fab' 
at pH 6.0 at 4°C. Later this material fonned a precipitate. This precipitate was re-
dissolved in TFA prior to MALDJ-MS confirmation. It was diluted 1:10 with pH 10.0 
Na2HP04 buffer with a final pH of 7.5 - 8.0 (measured by ColorpHast strips; EM 
Science) prior to making an emulsion with Freund's adjuvant. 
Immunization protocol - pilot study 
Ten female B 10.A mice (Jackson Laboratories, cat. # 000469) at 9 112 months 
were immunized with about 14 !lg total protein of the (9-40)Fab' -SMCC-HEL 
preparation (based on a calculated extinction coefficient of 1.9719 (glLr1cm-1 for the 1:1 
conjugate; see Appendix B), and five female B 10.A mice were injected with half of this 
amount. The mice recei ved about 60-70 !lg total protein for the secondary immunization 
(with the second batch, assayed by ELISA). Freund's complete adjuvant was used for the 
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Figure 5. The top HPLC chromatogram is of the T epitope by itself; the bottom is of the 
T epitope + SMCC reaction mixture, the product at 18.72 min being the desired peak. 
This peak was confirmed by MALDI-MS. The T epitope mass was 2112.02; the 
measured mass for the product was 2334.93 (expected: 2333.28) as well as various (0-8) 
Na+ peaks. Solvent A: water, solvent B: acetonitrile; 100 A phenyl (Rainin) with C18 
guard (Phenomenex). Gradient: 0-5 min, 5% B; 5-20 min, 5-100% B; 20-25 min, 100% 
B; 25-30 min, 100-5% B; 30-35 min, 5% B (wash). Diode array detection was used, but 
















Figure 6. MALDI-MS of (9-40)Fab' -Ac (i.e., acetylated to prevent sulfuydryl re-
oxidation) and of (9-40)Fab' -(T epitope), top and bottom respectively. The numbers are 
approximate due to the noise and peak width but are sufficiently accurate to determine 
that the synthesis succeeded. 
primary immunization and 15 days after the secondary. As with the ANOVA study 
below, the research adhered to the "Principles of Laboratory Animal Care" (NIH 
publication #85-23, revised 1985). 
Inlmunization protocol - ANOV A study 
For each group ten female BI0.A mice were injected subcutaneously with the 
above-mentioned antigens in a 1:1 (v/v) emulsion with Freund's adjuvant. Freund's 
complete adjuvant was llsed for the primary immunizations and incomplete adjuvant for 
the secondary immunizations. The mice were 11-13 weeks old for the Fab', Fab' -HEL, 
and Fab' + HEL cohorts and were 15-17 weeks old for the Fab'-(T epitope) cohort upon 
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their 1 ° immunizations. Assuming E = 1.9719 (glLr1cm-1 for the (9-40)Fab'-SMCC-HEL 
preparation, 6.7 llg of total protein (estimated 1.3 llg of actual conjugate based on the 
yield cited above) were injected for the primary immunizations, and 17.23 llg total 
protein (estimated 3.4 llg of conjugate) for the secondary, with the same nominal molar 
amount being used for the negative control cohorts (9-40)Fab' and (9-40)Fab' + HEL. 
The animals were bled 14 days after the primary immunization. The secondary 
immunization was 6 weeks, 3 days after the primary, and the 2° bleeding occurred 14 
days after the 2° immunization. The secondary immunization for the Fab' -(T epitope) 
cohort was 6 weeks, 6 days after the primary, with the bleeding 2 weeks after that. 
Deternlination of antibody response by ELISA 
A sandwich ELISA was used to measure the antibody response to the various 
vaccines. The capture molecules were Fab fragments (prepared by papain digestion as 
described in (54)) of 9-40,4-4-20, BV04-01, or BDCl. Digestion times were based on 
our experience in preparing Fab fragments for each individual antibody. Specifically, 
digestion times of 15 min, 60 min, 30 min, and 30 min were used for 4-4-20, 9-40, 
BDCl, and BV04-01, respectively. These were adsorbed onto polystyrene 96-well 
microtiter plates (Nunc MaxiSorpTM) for approximately 1 h, then washed with ELISA 
wash buffer (150 mM NaCl, 10 mM Tris, 1 mM EDTA, 0.01-0.05% Tween 20), then the 
serum was applied and incubated at room temperature for 1 h, then washed away, then 
the tracer antibody (goat anti-(mouse Fab) AP conjugate [Biodesign International]) was 
added and incubated for 1 h, then extensively washed away, and finally substrate (Blue 
Phos, KPL) was added and the absorbance read at 630 nm after 30 min. 
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ResuJts 
Pilot study response 
The purpose of the pilot study was to verify that we could make anti-idiotype 
antibodies with a Fab' -carrier protein construct such as described above. In order to 
establish that the response seen was truly anti-idiotypic, we used as controls the Fab 
fragments of three other murine antibodies (4-4-20, BV04-01, and BDCl) as coating 
antigens in the ELISAs. 4-4-20 is another anti-fluorescein antibody and is known to be 
idiotypically crossreactive with 9-40 (47, 49). BV04-01 is an anti-(ssdT) autoantibody 
derived from a murine model of lupus and shares the same framework regions on the 
heavy chain and almost the same light chain as 9-40 and 4-4-20 (28, 47). BDCl is also 
an anti-fluorescein antibody (IgG2a, K) that was developed in our laboratory but is not 
idiotypically crossreactive with 9-40 or 4-4-20. We performed full titrations and 
observed a very distinct "serum effect" in which the maximal response was not at the 
lowest dilution (Figure 7, Panel A). It was also clear from these pilot studies that the 
mice were generally giving a good anti-(9-40) response, although the interanimal 
variability was high. Furthermore, the response was anti-idiotypic as evidenced by the 
low anti-(BV04-01 Fab) and anti-(BDCl Fab) responses (Figure 7, Panels Band C 
respectively). In fact, while 4-4-20 is known to be idiotypically crossreactive with 9-40 
and the response is as one might expect (Figure 7), one mouse did show a weak anti-(9-
40 Fab) response but no anti-(4-4-20) response, thus clearly demonstrating the fine 
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Figure 7. FuJI titers for 2° anti-idiotype responses for all mice in pilot study (lst cohort 
after 2nd immunization.) The Fab coating antigens were 9-40 (Panel A), BV04-01 (Panel 
B), BDC1 (Panel C), and 4-4-20 (Panel D). 
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Figure 7, continued. 
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Lack of efficacy for T epitope (ANOV A study) 
Having established in the pilot study that the Fab' -HEL conjugate elicited an anti-
idiotype response in the mice, the immunological determinants of this response were 
explored in greater depth by comparison of Fab'-HEL to a Fab'-(T epitope) conjugate in 
which the carrier protein was replaced by a synthetic peptide. A mixture of Fab' and 
HEL (without crosslinking) and the Fab' itself were also included as negative controls. 
Analysis of variance was used to provide statistical weight to our concJusions (Table 2). 
The anti-(9-40) ELISA data for the secondary responses for the Fab-HEL, Fab, Fab + 
HEL, and Fab-(T epitope) cohorts is shown in Figure 8 Panels A-D respectively. The 
data for the primary immunizations were similar (data not shown). The pronounced 
serum effect seen in the pilot study is absent in these mice; it is not clear why this is the 
case. It is obvious that the anti-(9-40) response for the Fab-HEL cohort was significantly 
different from the response of the other cohorts (p = 4.89 x 10-13 by single factor 
ANOV A on the lowest dilution of the ELISA data (Table 2)), and it is equally cJear from 
the results that the anti-(9-40) response was negligible for the cohort immunized with the 
(9-40)Fab' -SMCC-(T epitope) preparation. 
Proof of anti-idiotype response for the ANOV A study 
Figure 9 shows a summary of titrations similar to those shown for the individual 
mice in Figure 8, except that only the Fab-HEL cohort is shown in Figure 9. The other 
curves shown are for the response to the various coating antigens used in the ELISA: 9-
40 Fab, 4-4-20 Fab, BV04-01 Fab, and BDC1 Fab. The anti-(9-40) and anti-(4-4-20) 
responses were the highest. Although the mice were not immunized with 4-4-20 antigen, 
4-4-20 is idiotypically crossreactive with 9-40 and so would be expected to also give a 
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Table 2: Statistical summary of cohorts. Single factor analysis of variance (ANOYA) 
was used to evaluate whether the immune responses observed from the different cohorts 
of mice were statistically different. (The single factor was the dose used.) These results 
are for the ELISA readings at the lowest dilution of the secondary response for cohorts of 
10 n1ice immunized with the denoted antigens. The low P-value clearly shows that the 
cohorts are not all the same. 
Table 2: Sing]e Factor ANOV Al 
Summary of ELISA variance: 
Groups 
Group 1: Fab'-HEL 
Group 2: Fab' 
Group 3: Fab' + tIEL 






Analysis of ELISA variance: 
Source of Variation SS 
Between Groups 1.3003 

























50.95 4.89 x 10-13 
F crit 
2.866 
* Notation used in Table 2: SS, sum of squares; df, degrees of freedom; MS, mean 
square; F, ratio of between-group variance to within-group variance; P-value, the 
probability of being wrong in asserting that a difference exists between the groups; F crit, 
the critical value of F in determining the P-value. 
positive response. It is remarkable, though, that the anti-(4-4-20) response is actually 
greater than the anti-(9-40) response (p = 0.03 by t-test). The anti-(BY04-01) response is 
present but mild, and the anti-BDC1 response is truly small, probably due to an anti-
framework antibody present in one of the mice, as this mouse also gave the highest anti-
(BV04-01) response. Taken together, these results give a good indication of the 
specificity of the response. 
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Figure 8. Secondary anti-(9-40 Fab) response for mice immunized with the following 
immunogens: Panel A, (9-40)Fab' -SMCC-HEL conjugate; Panel B, (9-40)Fab' + HEL 
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Figure 9. A veraged ELISA responses for various coating Ag after secondary 
immunization with (9-40)Fab'-SMCC-HEL. Summary of full ELISA titrations for 
different coatjng antigens for the experimental BIO.A mice (i.e., immunized with (9-
40)Fab' -SMCC-HEL). 
Discussion 
In both the initial pilot study and in the controlled study used for the ANOV A, 
anti-idiotype antibodies were generated in mice immunized with a Fab' -carrier protein 
construct «9-40)Fab' -SMCC-HEL). The anti-idiotype response has conclusively been 
shown for the mice in the experimental group, and not for mice in either of the control 
groups. As expected from the literature (48), 4-4-20 is crossreactive with anti-(9-40) 
antibodies and vice versa. There was a low level of anti-framework regions seen in the 
primary immunization (data not shown) but this seems to have decayed away with the 
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secondary immunization. Because BDCl was derived from BALB/c mice and therefore 
shares the same a]]otypic determinants as do 4-4-20 and 9-40, it is an excellent negative 
control for idiotype specificity. Had there been a significant response to BDCl, it would 
indicate either an anti-idiotype response (i.e., cross-reactivity with either 4-4-20 or 9-40) 
or an anti-a]]otype response. No significant anti-BDCl response was seen in either the 
pilot study or in the full ANOV A study. 
Contrary to our expectations, the Fab' -(T epitope) conjugate did not give an anti-
idiotype response. Possible reasons are poor processing or presentation of antigen, 
damage of the Fab' portion of the conjugate by the TFA needed to redissolve the 
material, or too Iowa dose (-277 pmol or less for the secondary, < 1/2 of this for the 
primary). (It is very unlikely that the dose was too high, given the typical 
recommendations for antibody generation (55).) This issue is resolved in the next 
chapter, in which a dose response study was undertaken using the same T cell epitope but 
with a simpler, more easily quantitated antigen (the hapten fluorescein) instead of the 9-
40 Fab' as the B cell epitope. The results strongly support the conclusion that the dose of 
(9-40)Fab' -(T epitope) was too low. 
Assuming then that it is only a quantitative matter of dose, it is still unclear why 
the immunodominant T cell epitope should fail as a carner protein replacement. To put it 
another way, why is a lower dose sufficient when other residues which contain 
subdominant or cryptic epitopes are also present? This would suggest that the outward 
phenomenological parameter of dosage is a surrogate for the more immunologically 
relevant, internal phenomena of antigen processing and presentation. Would a single 
chain Fv that incorporated the T cell epitope as part of its sequence have also failed to 
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e lici t an immune response in B 10.A mice? This is an intriguing possibility given the 
report in the literature (18) of a peptide that was derived from the hypervariable region of 
an anti-idiotype antibody, in which the peptide was both a B cell epitope and a T cell 
epitope. Although these authors did not incorporate this peptide as a canier protein 
substitute as such (i.e., they did not try to make an autologous protein immunogenic), this 
peptide by itself failed to generate a strong antibody response but did do so as part of a 
multiple antigenic peptide (MAP) construct. So while we thought that the old 
immunological paradigm of "a carrier protein is necessary to make a hapten or peptide 
immunogenic due to its large size" was incorrect, perhaps size does matter after all for 
secondary processing effects. The dose response work spans a 300-fold range 
encompassing the T cell epitope doses used herein. The results of that study are 
consistent with the results presented here as well as in (18) and other reports in the 
literature. 
FinaJly, it is worth noting that another anti-idiotype vaccine based on a patient-
specific, naked DNA vaccine that codes for a single chain Fv (Vical's Vaxid product) is 
in clinical trials (long term studies) for non-Hodgkin's lymphoma, with positive initial 
results reported slightly over a year ago (www.vica1.com). That construct relies on 
murine framework regions to provide T cell epitopes for human responses, which would 
SUppOIl the supposition that the T cell epitope in the present study could possibly work in 
a 1:1 vaJency with the idiotype protein (9-40 in this case) had they been fused together as 
part of a single polypeptide chain rather than attached somewhat extraneously through a 
crosslinker. Clearly that would have profound implications for peptide vaccines in 
general. As with increasing the valency (MAPs), such a result would be an effect of the 
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HO'V '''ELL CAN A T CELL E]>ITOPE REPLACE ]TS PARENT 
CAn.n.IEI~ pnOTEIN? PART 2: A DOSE RESPONSE STUDY 
Abstract 
To more fully explore the relationship between an immunodominant T cell 
epitope and the calTier protein from which it is derived, this work examines the dosages 
required for synthetic peptide vaccines containing a T cell stimulating epitope. 
Methods 
The hapten fluorescein (FL) was conjugated to chicken hen egg lysozyme (HEL) 
and to the following three synthetic immunogens: (1) the immunodominant T cel1 epitope 
of HEL in B IO.A mice, (2) a multiple antigenic peptide (MAP) form of this same T cell 
epitope, and (3) a negative control MAP in which the only non-core amino acid was 
glycine. Cohorts of BIO.A mice were immunized subcutaneously with equimolar 
quantities of FL-(T epitope) or negative control MAP at varying dosages spanning a 300-
fold range. The dose was not changed for the secondary immunization but was reduced 
I DO-fold for every cohort for the tertiary. 
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nesults 
For the primary immune response, the control (FL-GlYls)4-MAP gave no antibody 
response except at the highest dosage. The FL-(T epitope) immunogen showed a half-
sigmoidal dose response curve, linearly increasing above a threshold, although with 
moderately high variability in the responding animals. Increasing the valency of the 
immunogen to (FL-(T epitope))n-MAP (n = 2-4, due to variabilities in the degree of 
branching in a nominally 4-branched MAP core resin supplied by different vendors) 
resulted in dramatically increased immunogenicity at the lowest doses, but there was little 
change over the concentration range examined. The FL-HEL positive control showed a 
decreasing antibody response with increasing dose, although with fairly high variation 
among animals. The lowest dose with the FL-HEL was equivalent in antibody titer to the 
highest dose of the FL-(T epitope) peptide. For the secondary response, there was little 
evidence of affinity maturation, except that in the peptide FL-(T epitope) at low doses a 
strong all-or-none response was seen. Neither the (FL-(T epitope))n-MAP nor the FL-
HEL positive control showed a strong dose dependency, but now the FL-HEL was 
slightly more immunogenic than the MAP. Surprisingly, the tertiary response at 14 days 
was practically indistinguishable from the secondary response at 56 days. 
Conclusions 
The monomeric T cell epitope was at least 300-fold less potent than its parent 
canier protein. Incorporation of the epitope into a dendrimer such as a MAP increased its 
potency so that it was practically indistinguishable from the parent protein. This fully 
explained our earlier results in which the T cell epitope failed to replace the parent carrier 
protein. Furthermore, the negative control MAP worked as a probable TI-2 immunogen. 
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This control effectively removed antigen valency as a confounding variable. As to the 
use of "f\1APs as peptide vaccines, this work demonstrates that a vendor's quality 
assurance is sometimes insufficient and it is worthwhile to make small, easily analyzed 
test peptides using the same resins as those for which the desired MAPs are to be made. 
Introduction 
Peptides have been investigated as immunogens in vaccines since the 1980s, but 
initially only as haptens conjugated to a carrier protein. However, peptide haptens 
conjugated to canier proteins can be difficult to characterize due to variable degrees of 
labeling and variable batch consistency. Also, there is the possibility of eliciting an 
iInmune response to extraneous epitopes particular to the carrier protein, with the 
potential for allergies or other immunological side effects. Consequently it is 
advantageous to dispense completely with carrier proteins for human and livestock 
animal vaccines and to use instead well-defined, immunologically relevant peptides. In 
order to be effective (involving a T cell dependent response), a true peptide vaccine 
fonnulation must include one or more T cell epitopes that match the MHC haplotypes 
encountered in the population. With this in mind, several different phannaceutical 
approaches (liposomes (35-37), iscoms (56, 57), microspheres (58), numerous adjuvants 
(59)) have appeared in the literature with the goal of improving the efficacy of peptide 
(and other) vaccines. 
In 1988 Tam introduced the multiple antigenic peptide (MAP) consisting of a 
branched oligolysine core to which are attached the peptide epitopes of interest (10). 
This gives an advantage over the carrier protein approach in that it is a chemically well-
defined immunogen, as well as having other possible synthetic and safety issues. There 
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have now been over 150 papers involving MAPs, some using peptides as simultaneous T 
cell and B cell epitopes (60, 61), some using a more cassette approach with distinct T and 
B cell epitopes (62-64), and some comparing MAPs with the traditional carrier protein 
approach (65,66), Nevertheless, to the best of our knowledge, there have been no studies 
aimed specifically at addressing how well a T cell epitope can replace the carrier protein 
from which it is derived, from the pragmatic point of view of an in vivo immune 
response. 
The simplest way to address this question would be to do a t-test on animal 
cohorts immunized with a hapten (or equivalently, with a non-immunogenic protein 
against which an antibody response is desired) coupled either to a carrier protein or to a T 
cell epi tope deri ved from such a carrier protein. Considerable effort has gone into 
mapping many of these epitopes for a variety of proteins; one model protein used for 
immunological studies is chicken hen egg lysozyme (HEL) (44). Consequently, we 
initially compared a murine Fab' fragment conjugated to HEL with the same fragment 
conjugated to the immunodominant T cell epitope from HEL in an inbred strain of 
mouse, B lO.A (H-2a haplotype), Single-factor ANDV A on the lowest dilution of the 
ELISA results of the various cohorts showed clearly that the T cell epitope completely 
failed to render the murine antibody fragment immunogenic, whereas the carrier protein 
worked well in this regard (p = 4.89 x 10-13) (Chapter 3). This was contrary to our 
expectations, so we decided to do a more thorough investigation of how well an 
immunodominant T cell epitope compares to its parent carrier protein. The most 
quantitative way to do this was as a dose response study using well-defined and easily 
measured haptens for the B cell epitope. Fluorescein (FL) was chosen for this purpose 
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due to its ease of detection and to its widespread successful use as a hapten (67). Because 
peptides are generally believed to be non-immunogenic unless coupled to a carrier 
protein or incorporated into a MAP (or other special delivery system), we also included 
in our comparison a MAP version of the peptide, as we]] as a negative control MAP 
consisting of the same number of amino acids as in the experimental MAP, but with the T 
epitope sequence replaced by glycine residues. 
Four immunogens were prepared: FL-HEL, FL-(T epitope), (FL-(T epitope))n-
MAP (n = 2-4, see Methods), and (FL-(GlY)18)4-MAP, where (T epitope) is the 
immunodominant T cel] epitope from chicken hen egg lysozyme (HEL) for B 10.A mice 
along with its flanking residues (modified by replacing Cys-64 with Ser, thus: 
GSTDYGILQINSRWWSND) (45). Because the FL-HEL species is not a chemically 
well-defined species, there was some variability in the degree of labeling of the HEL with 
the FL (about 2-4 FL per HEL). 
We examined the primary, secondary, and tertiary responses over what we 
thought initially would be a wide enough concentration range to see the interesting region 
of the dose response function. This range was chosen based on the typical 
recommendations for protein immunogens, about 25 to 100 ~g per mouse (55). 
Consequently, in the present study we spanned 1 to 300 ~g per mouse for the FL-HEL 
case, as a positive control. This was converted to a molar basis and then the same epitope 
molar concentrations were used for the other immunogens. Because the primary and 
secondary immunization results showed that this range did not extend far enough into the 
low concentration region of the dose response curves for the FL-HEL and for the (FL-(T 
epitope)n)-MAP, the doses for a]] cohorts were reduced 1 DO-fold for the tertiary 
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immunization. The assay for nleasuring total antibody as a function of dose was a 
sandwich ELISA. 
l\1aterials and methods 
Preparation of FL-HEL 
BEL was purchased from Siglna, dialyzed against water, lyophilized, and stored 
frozen until use. Then it was dissolved in formamide and reacted with fluorescein NHS 
eSler, dialyzed, and lyophilized. There was still some undialyzed }""L remaining, which 
was removed by dissolving the FL-HEL in form ami de, diluting it with 
dimethylformamide, and then precipitating this out with diethyl ether. TLC showed that 
the removal of free FL was quantitative. Degree of labeling was assessed by MS and 
UV /VIS and found to be approximately 3. 
Preparation of f1uoresfeinated peptide inlmunogens 
A professional peptide synthesis facility located at the University of Utah 
synthesized the sequence GSTDYGILQINSRWWSND by batch method solid phase 
peptide synthesis using standard Fmoc chemistry both as the linear peptide and as a MAP 
construct using the tetrameric MAP resin supplied by Advanced ChemTech. This facility 
also prepared a control tetrameric MAP consisting of the same number of residues but 
with every residue replaced by glycine. The control MAP was synthesized using the 
letrameric MAP resin commercially available from Novabiochem; different suppliers 
were used for the two MAP constructs simply due to availability at the time. All of these 
synthetic peptides were fluoresceinated with 5- (and 6-) carboxyfluorescein using DCC 
as coupling reagent while still attached to the resin. 
Purit)! and structure asseSSlllent of fluoresceinated 
peptide inlnlunogens 
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Purity was assayed by HPLC and MS. The latter worked very well for the linear 
peptide and produced a mass within 1.0 dalton of the expected value. However, it had 
been the experience of the peptide synthesis fadlity, and also reported in the literature 
(68), that MAPs sometimes failed to give clean mass spectra. Nevertheless, both the 
experimental and contra] MAPs were analyzed by MS. MALDI-, ESI-, and FAB-MS 
failed to give interpretable and se]f-consistent spectra for the (FL-GlYI8 )4-MAP and 
MALDI-MS for the experimental MAP formulation showed mostly dimeric MAP. 
Although this latter result was unexpected, its validity was questionable for the reasons 
mentioned above. Thus, we turned to amino acid sequencing to validate the experimental 
MAP and amino acid analysis to validate the control MAP (amino acid sequencing was 
not thought to be productive for the control MAP because of its branched G1Yl8 
sequence). 
Amino acid sequencing of a small portion of experimental MAP that was left un-
fluoresceinated was found to be in agreement with the expected sequence. Comparison 
of the ratios of Gly: FL, Lys: FL, and Gly: Lys from amino acid analysis and UV 
spectrophotometry was done for the control MAP. (Note that although the MAP resins 
from both vendors were sold as a ~-Ala plus three Lys, so that taking Lys: ~-Ala would 
seem to be the most accurate measure, this turned out to be problematic because the 
different vendors - especially Novabiochem - used an excess of ~-Ala but capped it, 
resulting in an excess of ~-Ala, which rendered this ratio non-informative.) The expected 
ratio of G]y: Lys was 24: 1 and the experimental value by amino acid analysis performed 
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at the University of Utah's Amino Acid Analysis Facility was in agreement with the 
expected, within experimental uncertainty. Furthermore, the ratio of Gly:FL (expected, 
18: 1) was also acceptable within experimental error. Based on these results, the purity of 
the fluoresceinated peptide immunogens was deemed adequate for immunization. 
) J1ullunization protocol 
Male B 10.A mice (Jackson Laboratories, ME) from 4-6 weeks of age were 
immunized subcutaneously in two injections of ] 00 ~L each, with the dose comprised of 
a 1: 1 emulsion of the desired di1ution of the appropriate immunogen and Freund's 
complete adjuvant for the primary immunization or Freund's incomplete adjuvant for the 
secondary immunization. The animals were bled 2 weeks after they immunized for both 
injections by tai I vein or artery bleeding. The blood was allowed to clot in Eppendorf 
tubes, centrifuged and stored frozen. The primary, secondary, and tertiary immunizations 
were eight weeks apart. The research adhered to the "Principles of Laboratory Animal 
Care" (NIH publication #85-23, revised 1985). 
ELISA protocol 
ELISA test strips were purchased from Nunc and coated with a preparation of FL-
KLH (i.e., fluoresceinated keyhole limpet hemocyanin) made in our laboratory, diluted 
with a high-salt coating buffer (1.2 M NaCI, 50 mM NaP04, pH 7.5), All steps were 
done at room temperature. After coating the wells for 60-90 min, the plates were washed 
by tap de-ionized water and tap dried (turned upside down on paper towels sharply), then 
post-coated (blocked) with casein in ELISA wash buffer (150 mM NaCI, 10 mM Tris, 1 
mM EDTA, 0.01-0.050/0 Tween 20) adjusted to pH 11 with NaOH. After post-coating for 
-30 n1inutes the plates were washed again, then satnples were applied and serially 
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diluted. The plates were then washed and goat anti-(mouse Fab) (Sigma) was used in a 
I:] 0,000 dilution in ELISA wash buffer, then the plates were washed again. Substrate 
(Blue-Phos, KPL) was used but diluted 1: 1 with water, and the absorbances were read in 
a Titertech plate reader min after applying the substrate. 
Further anaJ)lsis of the 1\1AP resins using test peptides 
Our structure assessment of the experimental and control MAPs did not yield any 
information about the distribution of the number of branches per MAP, so we decided to 
have a test peptide synthesized at the same peptide facility using the same resins as were 
lIsed for the control and experimental MAPs. The sequence FLRG was made into a MAP 
llsing both the Novabiochem resin used for the (FL-GlYls)4-MAP and the Advanced 
ChemTech resin used for the (FL-(T epitope))4-MAP, and then analyzed by MALDI-MS. 
The MAP with the fonner resin was >95% tetramer whereas the latter resin gave mostly 
dimer with only one lysine as being the core; both are supposed to have a ~-Ala residue 
that is used for anchoring the growing peptide to the resin during synthesis. These results 
with the test peptide would strongly support the conclusion that the control MAP was 
predominantly tetrameric, whereas the experimental MAP was predominantly dimeric. 




Twenty-one cohorts of five mice each (Jess one that died) utilizing the above-
mentioned four immunogens at five different concentrations were immunized subcu-
taneously with their respective immunogen and complete Freund's adjuvant in a 1:1 (v/v) 
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emulsion. The vaccine dose range spanned from 65.0 pmol to 19.5 nmol (equiva]ent to 1 
- 300 )lg for the FL-HEL case). The dose was administered in two 100 J.lL injections. 
Concentrations were based on the fluorescein absorption with the assumption that for 
every mole of fluorescein there was a mole of T cell epitope, except in the case of FL-
HEL, in which the assumption was that for every 3 moles of fluorescein there was one 
mole of HEL, based on the degree of labeling seen in the MALDI-MS. The mice were 
bJed 2 weeks after immunization, and anti-fluorescein antibody responses were measured 
by ELISA. For the ELISAs each mouse had a fu}] titration done on its serum to be sure 
that there were no "serum effects," in which a maximum is seen in the response at a 
concentration that is not the nl0st concentrated, as we have occasionally observed in the 
past with other ELISA systems (69). This sort of effect was not seen in the sera of the 
mice analyzed (with one minor exception, excluding background variations), and in fact 
the precision of the assay was excellent. Figure 10 shows the titration curves for 4 
replicates of the same sample, showing a low intra-assay variability (CV = 6.5%). Figure 
11 shows the response at the 1.95 nmol dose for the FL-HEL, in order to more clearly 
show the differences in titrations from animal to animal. These results show clearly that 
the assay variability is much less than the mouse-to-mouse variability. The other samples 
in the ELISA were done with only one titration per mouse. 
The results from Figure 11 and other similar titrations from the primary 
immunization are summarized in Figure 12. Because there were almost no odd serum 
effects, the titrations generally decreased in response with increasing dilution, and so the 
best signal was with the highest concentration. The average of this highest-concentration 
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Figure 10 Intra-assay variability. Repeat titrations for mouse M-L in cohort M. These 
curves were for four polystyrene ELISA strips coated with fluorescein-KLH and blocked 
with casein to which the samples were applied and then subjected to two-fold serial 
dilutions. Goat anti-(mouse Fc) was used as the tracer antibody, washed, and then 
substrate was added and the color read after 63 min from the time at which the substrate 
was added. An intra-assay coefficient of variation (CV) of 6.5% was determined from 
these data. 
sake of clarity) being the standard deviations for the different mice in each cohort. For 
the primary immune response, the negative control (FL-GlY1S)4-MAP gave no antibody 
response except at the highest dosage. We surmise that this branched vaccine is acting as 
a type 2 T cell independent (TI-2) immunogen (33, p.2IO). The FL-(T epitope) 
immunogen showed a half-sigmoidal dose response curve, linearly increasing above a 
threshold, aJthough with moderately high variability in the responding animals. 
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Figure 11. Prirnary response for 19.5 JlM FL·HEL cohort. The five curves are 
titrations for the five mice in this cohort (designated as S). ELISA conditions are as in 
Figure 10. 
tope))n-MAP, resulted in dramatically increased immunogenicity at the lowest doses, but 
there was little change over the concentration range examined. Hence, it seems that 
increasing the valency of the peptide vaccine resulted in a strong shift in the dose-
response curve to the left. The experimental MAP gave the strongest overall primary 
antibody response an10ng the four immunogens. Finally, the FL-HEL positive control 
actually showed a decreasing antibody response with increasing dose, although with 
fairly wide variation among animals. This would suggest that tolerization is beginning to 
occur in son1e of the mice, even though Freund's complete adjuvant was used. The 
lowest dose with the FL-HEL was equivalent to the highest dose of the FL-(T epitope) 
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Figure 12. Prinlary dose-response functions for control and experimental 
inll11unogens in B10.A l11ice l11easured by ELISA with FL-KLH as coating Ag. This 
summarizes the primary immune response for all cohorts except for the adjuvant-only 
(infinite Ag dilution) cohort, due to the log scale. The adjuvant-only cohort was 
indistinguishable in response relative to the cohorts for the lowest concentration of (FL-
GlYls)4-MAP or of FL-(T epitope). Every datum shown represents the average of five 
mice per cohort, except for the second to lowest dose for the (FL-GlYIS)4-MAP negative 
contra], which had four mice (one died). The error bars are the sample standard 
deviations, shown either up or down for clarity. The arrow denotes the approximate dose 
used in Part 1 of this study, and therefore explains those results. 
Secondary response 
Freund's incomplete adjuvant was used for the secondary and tertiary immun-
izations. The dose was not changed for the secondary immunization for any of the mice. 
For the secondary response, there was some evidence of affinity maturation in the FL-(T 
epitope) immunogen and, surprisingly, in the (FL-GlY18)4-MAP immunogen, but not in 
the other two. (It is important to note, however, that because titers were being measured 
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rather than affinities, the increase in titer could be due to an increase in the number of 
cells in the responding cJones rather than to affinity maturation.) FL-(T epitope) at low 
doses exhibited a strong all-or-none response, as shown in Figure 13. Similarly, the 
negative control MAP showed one responder at a lower dose than previously. The newly 
respondi ng mouse in the intermediate dosage cohort was of the JgM isotype, whereas the 
other responding mice were primarily of the JgG isotypes. At the highest dose the 
response for (FL-GlYls)4-MAP was amplified in the secondary immunization over that in 
the prinlary, as shown in Figure 14. Because thymus independent antigens are believed to 
show little if any memory, one might conclude that this negative control vaccine is in fact 
1.2 ,... ... , .......... , ... " .... ,,,., .... , ......... , .. -.............................................. ---.... --------.--.---------------------, 
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Figure 13: Secondary response for 0.65 J.lM FL .. (T epitope) cohort. Two mice 
showed strong secondary responses but three showed no response in this low dosage 
cohort. The next higher dosage was similar. The ELISA conditions were as in Figure 10 
and Figure 11. 
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Figure 14: Sl'condary dose-response functions for control and experimental 
inl111Unogens in B10.A mice using EL1SA with FL .. KLH as coating Ag. This is 
analogous to Figure 12, and again the infinite dilution (adjuvant only) cohort is not 
shown but gave no response. The very wide error bars in the FL-(T epitope) case is due 
to the strong all-or-none response shown in detail in Figure 13. 
acting in a T cell dependent fashion. This is certainly possible but would be difficult to 
reconcile with CUITent understanding of how peptides are presented in the MHC and 
recognized by the T cell receptor. We be1ieve that it is more likely that this negative 
control irnmunogen is in fact a T cell independent immunogen, but that class switching 
and possible affinity maturation are nevertheless being seen. 
Affinity maturation was not observed for either the FL-HEL or the (FL-(T 
epitope))n-MAP immunogens. The doses of these immunogens were already in the 
saturation region of the dose response curve, so there is little, if any competition for 
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antigen and hence very lin1ited selective pressure on high affinity c10nes in the genninal 
centers (70). Neither the (FL-(T epitope))n-MAP nor the FL-HEL positive control 
showed a strong dose dependency in the concentration range examined. Also, the FL-
HEL was now slightly more in1munogenic than the MAP at every concentration used. 
results are summarized in Figure 14. 
Tertiary response 
Prior to immunizing the animals the third time, the mice were bled so that 
calTyover from the secondary immunization could be estimated. Those results are shown 
in Figure 15 and the results of the tertiary in1munization in Figure 16. As can be seen, 
there is still considerable carryover from the secondary immunization even after 56 days. 
This makes it difficult to say how much of the response from the tertiary is due to the 
tertiary immunization and how n1uch is just carryover fron1 the secondary imnllmization. 
As can be seen from Figure 15 and Figure 16, there is little difference between the two. 
Comparing Figure 14 and Figure 15 shows that for the middle dose of the (FL-GlY18)4-
MAP in Figure 14 there is a small (1 mouse out of 5) response, but that this is gone in 
Figure 15. The reason is simply that this mouse died in the interim. The most striking 
observation is that the response for the FL-(T epitope) immunogen is higher at 56 days 
than at 14 days, and the others are still about as high. Probably this is due to the 
sustained release of the vaccine, adjuvant mixture. 
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Figure 15: Secondary dose-response functions 56 days postimnlunization for 
control and experitnental inlnlunogens in Bl0.A mice using ELISA with FL-KLH as 
coating Ag. This shows the carryover from 2° immunization, 56 days post-
immunization. This is analogous to Figure 12 and Figure 14, but now more mice had 
died. The middle dose for the FL-(T epitope) cohort, the middle and second-highest 
control MAP dose COhOI1S, and the second-highest and highest doses of the (FL-(T 
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Figure 16: Tertiary dose-response functions for control and experimental 
inllllunogens in B 10.A nlice using ELISA with FL-KLH as coating Ag. Results of 3° 
immunization. No further mice had died from those in Figure 15. 
Discussion 
Four different immunogens (vaccines) were prepared and characterized, and then 
injected into mice known to be responsive to the T cell stimulating epitope used in two of 
these immunogens (the mononleric and the tetrameric FL-(T epitope) species). These 
vaccines were 0) the FL-HEL used as a positive control; (2) the FL-(T epitope), where 
the "T epitope" is the immunodominant T cell stimulating epitope from HEL in B 10.A 
mice; (3) the dendrimeric multiple antigenic peptide version of the f1uoresceinated T 
epitope, designated (FL-(T epitope»n-MAP; and (4) a control MAP wherein the eighteen 
residues in the T epitope were replaced by glycine. The anti-FL titers were compared for 
each of these vaccines in the primary, secondary, and tertiary responses. Of the six 
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possibJe pairwise comparisons between the four immunogens at a given point in time, the 
three most meaningful are 0) between the monomeric and mu1timeric versions of the 
f1uorescei nated peptide; (2) between the monomeric fluoresceinated peptide and the 
intact I-fEL; and (3) between the experimental MAP (i.e., the (FL-(T epitope))n-MAP) 
and FL-HEL. The latter two comparisons address the question originally posed, i.e., how 
well a T cell epitope can substitute for its parent carrier protein in terms of generating an 
antibody response. The negative control MAP is useful in accounting for the effect of 
multi valency of the FL in the FL-HEL and in the (FL-(T epitope))n-MAP, which would 
otherwise be a confounding variable. 
Comparing the monomeric vs. the multimeric MAP versions of the 
tluoresceinated peptide clearly shows a dramatic increase in the effectiveness of the T 
cpitope upon incorporation as part of a MAP. ** This is consistent with earlier studies 
comparing the valency of different monomeric or mu1tiple antigenic peptides (62), but 
also extends these results across a much wider concentration range. However, the 
multimeric MAP was not nearly as easy to prepare in good purity as was the monomeric 
peptide of the same sequence. In fact, although initially we believed that there was a 
problem with the mass spectra for the (FL-(T epitope)4)-MAP and so decided to proceed 
with the immunizations based on the satisfactory amino acid sequencing results, we later 
** One possible objection to this statement would be the possibility that the increased 
titers seen in the ]\.1AP cohorts were due to increased background (decreased specificity) 
rather than increased potency of the T cell epitope. This could be tested directly by 
perfornling a series of ELISAs on related haptens similar to fluorescein, although this 
was not done. This alternative explanation also seems unlikely given the fact that not 
only have MAPs been observed to increase the potency (or decrease the specificity) in a 
very wide range of B cell epitopes, they have also been shown to be effective in 
increasing the potency of cytotoxic T cell epitopes as well (71-73), which would suggest 
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learned that the actual (FL-(T epitope)4)-MAP was a minor species, perhaps 15-20% of 
the total, based on PAGE and on the results of a sma11 test peptide made on the same 
MAP resin. (The vast majority of this MAP formulation was a dimeric MAP based on 
only a single Lys for the core; see Materials and Methods for details.) While this does 
compronlise the results of the dose response study in terms of pharmacodynanlic 
pararneters which one might delive particular to the individual inlnlunogens (fitted 
perhaps to a sigmoid maximum effect model), it actua]]y strengthens the central 
conclusion, namely that T cell epitopes incorporated into MAPs are far more potent than 
linear peptides on an epitope molar basis except at extremely high (mid-nmol) doses, 
where they become equivalent. It is impossible to say how much of the CFL-(T 
epitope))n-MAP cohorts' antibody responses were due to true (FL-(T epitope))4-MAP and 
how much were due to dimeric species based only on the present evidence. Since the 
(FL-(T epitope))n-MAP cohorts exhibit a plateau as it is, it is unlikely that highly purified 
(FL-(T epitope))4-MAP would show a dose response curve markedly different from what 
was observed. However, had lower concentrations been used, then this difference likely 
would become apparent. (It is also possible that had highly pmified (FL-CT epitope))4-
MAP been used, that tolerization sinlilar to that seen with the FL-HEL might have 
occuITed and been mistakenly interpreted as evidence that MAPs are only marginally 
more effective than are monomeric peptides.) In such a case it would be very interesting 
to see whether the steepness of the curve (related to the exponent in a sigmoidal 
maximum effect model) cOITe]ates with the number of branches. 
that their mechanism of action does increase potency at the T cell epitope level rather 
than decrease the specificity of the humoral response. 
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The biological reason for why oligomerization shifts the dose response curve 
strongly to the left is not well understood but possibly has more to do with antigen uptake 
by antigen presenting cells rather than with antigen processing. (One might expect that 
the monomeric peptide would require Jess processing than would the tetrameric MAP, 
and possibly that dendritic cel1s would more easily recognize a larger, multivalent species 
than a smaller peptide.) Because of the high analytical sensitivity of the fluorescein 
hapten, it may be possible to test this hypothesis in the future with these constructs. 
As for the original question of how well a T cell epitope can replace the carrier 
protein from which it is derived, a comparison between the monomeric peptide and the 
can-ier protein shows that the immunodominant peptide from HEL for BIO.A mice is at 
least 300 times Jess potent at stimulating a T cell dependent response than is the intact 
can-ier protein. It is worth noting that FL-HEL is also monomeric in terms of the 
immunodominant T cell epitope but is roughJy trimeric in terms of the hapten fluorescein. 
However, when the T cell epitope is incorporated into a MAP, there is little difference 
between the MAP and the carrier protein, with the MAP possibly being slightly more 
potent for the primary response and the carrier protein slightly more potent for the 
secondary response, although there is considerable variability within cohorts. The 
present data could also explain why there was no effect seen in Part 1 of this study: the 
dose of the Fab' -(T epitope) conjugate was in the nonresponding, flat portion of the T 
epitope curve, whereas at this same dose the carrier protein HEL is fully potent. 
B cells can differentiate into antibody secreting plasma cells by one of three 
known mechanisms: (1) direct stimulation by a T helper cell specific for the same antigen 
(albeit different epitopes) as is the B cell, (2) activation by a type 1 T cell independent 
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(Tl-1) response (which ~lctualJy does have some T cell dependency), or (3) activation by 
a type 2 T cell independent (TI-2) response (which is truly T cell independent) (33). TI-l 
responses involve polyclonal B cell activators, but TI-2 responses rely on receptor 
crosslinking and therefore require that the antigen be polymeric or at least multimeric 
with respect to the epitope recognized by the reactive B cell clone. In the present case 
this would mean that the valency of the FL-HEL with respect to FL, and likewise of the 
(FL-(T epitope»)n-MAP, is, strictJy speaking, a confounding variable; the response seen 
could be due to the B cell receptor crosslinking or it could be due to specific assistance 
by helper T cells. However, the negative control (FL-GlY18)4-MAP does effectively 
control for B cell receptor crosslinking. (It was made with a different manufacturer's 
resin and the same test peptide made with this resin gave >950/0 tetrameric MAP; again, 
see Materials and Methods for details.) Hence, the response seen in the case of the FL-
HEL was due to the irnn1unodominant and subdominant epitopes present in HEL, and not 
due to direct crosslinking of the B cell receptors, at least at the lower concentrations used. 
Likewise, the response due to the (FL-(T epitope»)n-MAP preparation is not simply due to 
B cell receptor crosslinking but rather involves T cell help. Also, because crosslinking is 
concentration dependent, it is reasonable to assume that the anti-FL response seen in the 
control MAP at the highest concentration is due to B cell receptor crosslinking of FL-
specific clones, and that this response should not exist at lower concentrations. 
Nevertheless, it is noteworthy that one mouse did show a primary response at a lower 
(intermediate) concentration after the second immunization. 
It is also interesting that while this was original1y intended as a dose response 
study over a fairly broad concentration range, the optimal concentrations were not known 
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a priori and it can be seen from Figure 12 that the concentration range used shows a 
significant dynamic range only for the FL-(T epitope) species. The (FL-(T epitope»n-
MAP function has reached a plateau in its dose response curve, which is presumably 
sigmoidal in appearance. However, unlike most other saturation phenomena in biology, 
T cell stimulation with respect to increasing antigen dose does not simply reach a stable 
plateau but rather exhibits a maximum. It is well known that at "high" antigen doses T 
cell anergy or deletion become operative (33, Ch. 10), and this is beginning to be seen in 
Figure 12. 1t is somewhat surprising that this tolerization is seen over a concentration 
range typically used for protein antigens, but it should be remembered that HEL is a low 
molecular weight protein and so a typical dose of 50 to 100 Jlg of BEL corresponds to a 
greater number of molecules than 50 to 100 Jlg of a higher molecular weight protein. 
Presumably if the concentration range used had been over a much wider scale, 
then the (FL-(T epitope)n-MAP would also show a decrease in response at very high 
doses and a sigmoidal response at lower doses. Instead the response is essentially flat 
over the 300-fold concentration range used. Likewise, the control MAP should continue 
to show a higher level of stimulation at higher concentrations, but because T cell 
stimulation and anergy are not issues for T cell independent means of B cell stimulation, 
it is unclear if a decrease would be seen at extremely high levels of antigen (tens to 
hundreds of nanomoles). At such high levels one also runs into the difficulty of 
solubility; the (FL-GIYls)4-MAP is not as soluble as one might expect based on its 
structure. Furthermore, at such extremely high doses it is possible that secondary effects, 
such as unexpected toxicity, may become important. 
74 
No affinity maturation was seen for the FL-HEL or for the (FL-(T epitope))n-
MAP, probably due to the fact that antigen competition is not Hmiting in the case of 
saturating responses. However, affinity maturation is seen in the negative control MAP, 
which is surprising, and in the FL-(T epitope) iJnmunogen at the lowest doses but only in 
some Jnice. Class switching does seem to be occurring based on the fact that the newly 
stimulated mouse in the intermediate concentration of control MAP is of the IgM isotype 
whereas the other secondary response data for responding mice are of IgG isotypes (data 
not shown). 
The data show a trade-off between intensity of response and number of 
responders in the secondary immunization for low concentrations of FL-(T epitope). One 
might expect this to also be seen with the other antigens as well in their lower portions of 
their respecti ve curves. Sampling lower concentrations was done in the tertiary 
immunization but the results are practically indistinguishable from the carryover of the 
secondary even after 56 days. Measuring carryover after the primary immunization was 
not performed since the literature would indicate that the B cell activation is at a 
maximum after nearly 2 weeks (74), and since we expected to see an increase in titer due 
to the inlmunization. In hindsight, this should have been done, especially given the 
presentation in the literature (albeit for guinea pigs) that the ELISA titer to MAPs is 
highest at about 28 days and barely drops thereafter even to 56 days (66). 
Finally, it should be noted that commercially available, off-the-shelf MAP resins 
do not always yield the products that they are supposed to, and it is advisable to first 
synthesize a small test peptide that one can use to verify the quality of the resin for a 
longer run, or else to double-check the qua1ity control of the vendor's lot used. The 
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MAPs used in this paper were synthesized using the same level of care as are ordinary 
peptides routinely synthesized at the University of Utah's Peptide Facility, but one 
vendor's resin gave mostly the expected four-branched MAP whereas another's gave 
mostly two-branched MAP. 
CHAPTERS 
AN lNVEST1GAT10N INTO HOW 'VELLAN lD10TOPE PEPTIDE 
l\11l\11C CAN REPLACE lTS PARENT IDIOTYPE 
Abstract 
Purpose 
This study's motjvation was to evaluate how we]] an idiotope peptide mimic of 
the third complementarity determining region of the heavy chain (CDR-H3) of an 
antibody could substitute for the entire idiotype of an antibody, with the ultimate goal of 
using such a peptide mimic in a vaccine formulation for targeting pathological B 
lymphocytes. 
Methods 
The protein chicken egg lysozyme (HEL) was used as a carrier protein, to which 
was attached viu SMCC either the Fab' fragment of mAb 9-40, or else the B epitope 
peptide mimic (HBep"). Cohorts of BIO.A mice were imn1unized subcutaneously with 
Freund's complete (10 in1munization) and then incomplete (2° and 3° immunizations) 
adjuvant. Bep und Bep + HEL negative control cohorts were also used. Serum was 
assayed by ELISA for anti-peptide and anti-(9-40 Fab') activity. 
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Results 
As expected, antibodies against the B epitope were generated with the B-HEL 
conjugate, and antibodies against the intact idiotype were generated with the (9-40)Fab'-
HEL conjugate. No crossreactivity was seen for these two responses for the primary 
imnlLmization. After boosting with the secondary dose, crossreactivity was seen in 3/10 
of the mice inlnlunized with the B-HEL conjugate. A strong serum effect, in which there 
was a maximum response for an intermediate dilution, was seen in the ELISAs for the 
crossreacting mice. Little or no crossreactivity for the peptide was seen in mice 
immunized with the (9-40)Fab' -HEL conjugate. In all cases the negative control mice 
cohorts showed negligible response. The fraction of crossreacting mice increased with 
continuing immunizations, fronl 0 to 3/10 to 5/8 (two died). 
Conclusions 
A fair crossreactivity was demonstrated for an idiotope peptide mimic in relation 
to the intact idiotype. In accord with other reports this paper demonstrates the potential 
for this methodology as a therapeutic vaccine, but it is probably insufficient by itself to 
supplant intact idiotype, carrier protein fusion proteins (or conjugates) by means of 
idiotope peptide mimics. However, the increase in crossreactivity seen with increasing 
immunizations suggests that an assortment of idiotope mimics based on two or more 
CDRs, or perhaps co-immunization with the idiotype, would be a suitable area for further 




Cancer vaccines reJy on antigens expressed uniquely or at least predominantly on 
cancer ceJJs in for them to achieve specificity. Ideally, the cancer antigen should be 
unique to the cancer cell, and this is the case in most lymphomas and leukemias. 
Typically only one or a few clones is involved in the pathologytt (4, 75), and the 
cancerous lymphocytes express on their surfaces either T cell receptors (TCRs) (as in the 
majority of lyn1phomas) or B cell receptors (BCRs). Because of the gene rearrangement 
invol ved in the ontogeny of these celJ lines, the particular BCR or TCR is unique to the 
clone that encodes it and thus serves as an operational definition of that clone. Hence, the 
idiotype the unique portion of a TCR or a BCR - presents an ideal target for 
immunotherapy for lymphocyte cancers. This ideal specificity nevertheless comes at a 
cost: it becomes necessary to personalize the immunotherapy to each patient's 
pathological c]one(s). 
In the early years following the introduction of monoclonal antibody technology 
this sort of specific immunotherapy was attempted by raising murine monoclonal 
antibodies and then using these as an experimental treatment for lymphoma patients. 
This sort of approach has been undertaken by several groups, notably Ronald Levy's at 
Stanford University (15,25,75-94) and Freda K. Stevenson's of Southampton University 
Hospitals, UK (14, 26, 27, 95-98), and has the disadvantages that specific monoclonal 
anti bodies need to be prepared for each patient, which takes precious time and is 
tt From an immunological perspective, with a clone operationally (serological1y) defined 
by its idiotype, this is a true statement. However, one should bear in mind that other 
genotypic alterations (mutations, chronlosomal rearrangements, aneuploidy) may exist 
that do not result in an idiotypic difference but which nevertheless result in a 
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ex pens] ve, and that the antibodies used were mouse antibodies and could engender a 
human anti-mouse antibody response (12), although the toxicity was reported to be low 
(75). The initial idea was to use such monoclonal antibodies as molecular homing 
devices for another therapeutic agent such as a conjugated toxin or radioactivity (75), but 
in fact the BCR target is such that if it is crosslinked by antigen or anti-idiotype 
antibodies without a second, activating signal, apoptosis ensues and so the antibodies 
alone also proved surprisingly effective. Furthermore, it can be difficult to obtain 
sufficient quantities of purified patient-specific antigen, so other less ideal molecular 
targets have also been pursued, e.g., CD20 (75) but not surprisingly these also target 
some healthy cells. 
The historical method of producing anti-idiotype antibodies has been to immunize 
another species with the idiotype antibody and then to absorb out the anti-al1otype and 
anti-isotype antibodies (12). For an anti-idiotype antibody therapy to work it should 
ideally be possible to generate such anti-idiotypes with minin1al material. There are two 
ways that such immunotherapy could be accomplished, and both have been tried: either 
one could generate anti-idiotype antibodies and use these alone or in combination with 
other therapy for the treatment of active disease, or else one could make a therapeutic 
vaccine to educate the patient's own immune system to recognize the pathological clones 
as being foreign and hence to mount an immune response against them. According to 
Ronald Levy's perspective, the fomler approach is more suitable for patients in relapse 
while the latter approach is more suitable for patients in remission (75). It would be 
preferable if one could simply use the cDNA from a biopsy to determine the idiotype of 
polyclonality that could be detected by subtractive hybridization or other biochemical or 
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the pathological clone and then to generate anti-idiotype antibodies based on this 
information (99). One possibility to achieve this would be to use a single-chain variable 
fragment (scFv), carrier protein fusion construct based on the idiotype as a therapeutic 
vaccine. Vical, Inc. announced positive phase IIII clinical trial results of personalized 
DNA vaccines encoding an scFv (with murine constant region domains to make it 
foreign) under the brand name Vaxid (www.vical.com. March 27, 2001 press release). 
Another approach has been to use tobacco viruses encoding the idiotype as an insert (90). 
Both approaches have shown positive results in animal models. 
Yet another possibility would be to make a peptide mimic based on one or more 
of the idiotopes that comprises the idiotype, and then to use the idiotope mimic as a 
vaccine to generate anti-idiotope antibodies in the hope that they wi1l also crossreact with 
the parent idiotype. This approach was undertaken in the 1980s in animal models by 
groups using linear peptides corresponding to the either the first (20), second (20, 21, 23), 
or third CDR of the heavy chain (20, 22, 100, 101). One study involved an idiotope 
peptide mimic of the second CDR of the light chain of a human autoantibody (24), The 
third hypervariable region of the heavy chain - the CDR-H3 loop - has been shown to be 
superior to the other loops with respect to making crossreactive antisera (20). In general, 
these approaches found that the anti-peptide anti-sera produced in another species were 
crossreactive with the parent idiotype antibody. However, only a few (22, 23) of these 
studies actually compared the crossreactivity between the idiotype and the idiotope 
minlic directly in terms of immunizations, and those comparisons were flawed to a 
degree because the foreign T cell epitopes used were not the same. (They used the mouse 
genetic techniques. 
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antibody itself but in another species to make it foreign, whereas the peptides were 
coupled to KLH instead.) This is the focus of the present study - to compare directly an 
idiotope-canier protein immunogen versus an idiotype-carrier protein immunogen. 
The particular antibody chosen as the idiotype for this study is 9-40, a murine 
anti-fluorescein antibody of mediun1 affinity (46) belonging to a family of clonotypical1y 
related anti-fluorescein antibodies whose idiotypes have been well characterized (47-51). 
Because we intended to study a peptide mimic of the idiotype as a vaccine, it was 
necessary to deri vutize the idiotype antibody in order to make it foreign to the mouse 
immune system. Consequently we chose to use chicken hen egg lysozyme (HEL) as a 
carrier protein due to the fact that this protein has been well studied chemically and 
immunologically (44), and is small (14.3 kDa), cheap, and easily dissolved. Because it is 
easier to ascertain whether coupling between the carrier protein and the idiotype has been 
successful when the relative change in molecular weights is large, we used the Fab' 
fragment of 9-40 as the idiotype rather than the intact antibody. Hence, the 9-40 Fab' 
fragment acts as a giant hapten. \Ve also used the CDR-H3 as the idiotope peptide mimic 
(hereafter designated the B epitope) likewise coupled to HEL. An important 
consideration is whether or not a linear peptide or a cyclic peptide should be used. 
Although the earliest studies of idiotope peptide mimicry reported good crossreactivity 
with just a linear peptide (22-24, 100, 101), other studies found no crossreactivity with a 
linear peptide (Prof. David M. Kranz, University of Illinois at Urbana-Champaign, 
personal communication), and we felt that a cyclic peptide would be superior, so our 
peptide mimic was cyclized. Negative controls were with the B epitope and the HEL 
simply mixed together rather than covalently coupled, and with the B epitope by itself. 
l\1ateria1s and methods 
Preparation of the (9-40)Fab'-HEL 
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The (9-40)Fab' -HEL conjugate was prepared as described in Chapter 3 and 
elsewhere (69). Briefly, HEL was dissolved in pH 7.99 PBS and then derivatized with a 
large (-1 OO-fold) excess of SMCC (Pierce) for several hours at room temperature. 
Excess SMCC was removed by SEC (PD-IO column [Amersham Phannacia], eluted with 
PBS). This was set aside untll the (9-40)Fab' had been prepared and purified by SEC (as 
described in Chapter 3). The purified (9-40)Fab' in its elution buffer (0.1 M NaP04 , pH 
6.0, 5 mM EDTA) was then immediately added to the derivatized lysozyme and allowed 
to react ovelllight at 4°C. The product was purified by size exclusion chromatography 
and the fractions were assayed for both murine (i.e., 9-40) Fab' and for BEL by ELISA; 
both tested positive. 
Preparation of the B·HEL 
The 9-40 CDR-H3 idiotope peptide mimic (disulfide of GGGCTSYGYHGA YC, 
designated as the B cell epitope or Bep for short - it includes an N tenninal triglycyl 
spacer), was prepared by standard Fmoc solid phase peptide synthesis by the University 
of Utah's DNA/Peptide Facility. It was characterized by MALDI-MS and found to be in 
agreement with the expected mass (1395.5 expected vs. 1393.47 measured). 2.0 mg of 
HEL were dissolved in 70 JlL of fonnamide, then diluted with 20 JlL of PBS. 1.0 mg of 
Bep was dissolved in 70 JlL of DMSO, then diluted with 20 JlL of PBS. 2.0 mg of DSG 
were dissolved in 40 JlL of DMSO and then transferred to the Bep solution for 5 min. 
Excess DSG was removed by precipitating the reaction mixture with THF ( ..... 2 mL) and 
then El0Et, then centrifuging. The DSG-Bep conjugate was then redissolved in 40 JlL of 
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DMSO and then added to the HEL solution and aJIowed to react overnight. 
Characterization was by MALDI-MS (Figure 17) and then reconfirmed after a period of 
storage by SDS-PAGE (Figure 18). As can be seen clearly in Figure 17, not all of the six 
Lys residues on HEL were derivatized; there are peaks corresponding to 0, 1, 2, and 3 
Bep per HEL. This is to be expected based on steric considerations of the Bep as well as 
the reported unequal reactivity of HEL's six Lys (102). (In that study, Lys 33 was the 
most reactive, followed by Lys 97 and Lys 116, whereas Lys 1 [and the N terminus 
itse]f], Lys 13, and Lys 96 were unreactive.) 
Inlnlunization protocol 
Cohorts of female B 10.A mice (H-2a haplotype; Jackson Laboratories, cat. # 
000469) 3-5 weeks old were injected with 65 pmol of either the B-HEL conjugate, the (9-
40)Fab' -BEL conjugate, B + HEL mixture, or B by itself. The concentrations of the 
Fab' -HEL and the Bep-HEL were estimated based on scanned electropherograms or mass 
speclronletry integrated peak heights using the software Un-Sean-It (Silk Scientific, 
Provo, Utah) and adjusted molar extinction coefficients calculated from Trp, Tyr, and 
Phe residues (103) (see Appendix B). Thus, 65 pmol of Bep-HEL is the total amount of 
(Bep)-HEL + (Bep)2-HEL + (Beph-HEL, for example. Mice were bled by tail vein or 
artery 2 weeks later (primary and secondary; 16 days for tertiary). They were also bled 
prior to the boosts as described in the Results. All immunogen preparations were mixed 
1:1 (v/v) with Freund's complete adjuvant for the primary immunization and with 
Freund's incomplete adjuvant for the secondary and tertiary immunizations. Each 
immunization consisted of two subcutaneous injections of 50 JlL. The research adhered 
to the "Principles of Laboratory Animal Care" (NIH publication #85-23, revised 1985). 
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Figure 17. MALDI-MS of (Bep)n-HEL reaction mixture product. n = 0-3. The mass of 
the peptide plus DSG is 1395.5 + 98.1 = 1493.6, and HEL's mass is 14314, so the 
approximate expected masses are 14314,15808,17301, and 18795 amu. Given the fairly 
wide peaks, the measured masses are consistent with these theoretical values. 
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-
Figure 18. With PhastGel, migration is shown from bottom (negative) to top (positive). 
From left to right, bands are low m.w. markers, HEL (which dimerizes), and the (Bep)n-
HEL product, n = 0-3. 
ELISAs 
Nunc MaxiSorpTM plates were coated for 1 h with either 9-40 F(ab')2 or with a 
Bep-BSA conjugate made analogously to the Bep-HEL conjugate described above or 
with BSA as control, then post-coated (blocked) with 1 gIL casein solution (in ELISA 
wash buffer, 150 mM NaCI, 10 mM Tris, 1 roM EDTA, 0.01-0.05% Tween 20) for 30-
60 min, then serum samples were applied and incubated at room temperature for 1 h, then 
washed away, then the tracer antibody (goat anti-(mouse Fab) AP conjugate [Biodesign 
lntemational]) was added and incubated for 1 h, then extensively washed away with 
deionized water, and finally substrate (Blue Phos, KPL) was added and the absorbance 
read at 630 nm after 30 min. The specificity of response was measured by sandwich 
ELISAs as described previously in Chapter 3 and elsewhere (69) with Fab fragments of 
9-40,4-4-20, BV04-01, or BDCl. 
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Results 
The specificity of the anti-idiotype antibody response was established in pilot 
studies with female BALB/C mice immunized with (9-40)Fab' -HEL conjugate as part of 
another study (Chapter 3 and (69». This was done by using Fab fragments of four 
different antibodies as ELISA plate coating antigens: 9-40,4-4-20, BV04-01, and BDCl. 
4-4-20 is a high-affinity anti-fluorescein antibody that is idiotypically crossreactive with 
9-40 and is clonotypically related to 9-40 (47, 49). BDC1 is another anti-fluorescein 
antibody, developed in our laboratory, which is not idiotypically crossreactive with 4-4-
20 or 9-40. BV04-01 is an anti-ssdT antibody that has extensive homology with 9-40 in 
the light chain but has only about 60% homology in the heavy chain (28). These results 
are seen in Figure 19 for the primary response and in Figure 20 for the secondary 
response. Oddly, the response for BV04-0l Fab was higher than the response for 4-4-20 
Fab in the primary immunization (although not in the secondary). These measurements 
were repeatable (data not shown). 
Having established the specificity of the (9-40)Fab' -HEL anti-idiotype response, 
the next question was how well an anti-idiotope peptide mimic can crossreact with the 
parent idiotype, i.e., the focus of this study. Figure 21 and Figure 22 show the average 
primary response for all mice after 2 weeks. By this time there was an anti-idiotype 
response (Figure 21) but no anti-idiotope response (Figure 22). As a negative control for 
the ELISA, an anti-BSA response was also measured and found to be negligible (Figure 
23). However, by 44 days postimmunization, there was an anti-idiotope response (Figure 
24), with again no anti-BSA response (Figure 25). The anti-idiotype response was still 
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Figure 19. These data are the titration curves for the primary immunization of the fifteen 
BlO.A mice used in the pilot study to determine how specific the anti-idiotype response 
was. The indi vidual mice are in the key to the right with the letter designating in which 
cage they were stored and the -0, -L, -R, -B, and -OFF suffixes designating how their ears 
were cut. See text for assay details. Panel A is for the anti-(9-40 Fab) response, Panel B 
is for the anti-(4-4-20 Fab) response, Panel C is for the anti-(BV04-01 Fab) response, and 
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Figure 20. These data are as in Figure 19 Panels A-D except that the samples were for 
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Figure 20, continued. 
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Figure 21. As the title indicates, these data are for the anti-idiotype response 2 weeks 
after primary immunization. The error bars represent the interanimaI variability as given 
by the sample standard deviations for the four different cohorts. The slight increase in 
response for all the cohorts with increasing dilution is apparently a systematic error of 
this particular assay instance. Clearly, only the mice immunized with the idiotype 
















Anti-(Bep-BSA) titers 2 weeks after primary immunization 
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Figure 22. These data show the anti-idiotope response for the primary response of the 
four cohorts, similar to the data in Figure 21. 
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Figure 23. Since BSA was used as a protein to which the peptide was conjugated in 
Figure 22 in order to increase its adsorption to the polystyrene plate used for the assay, it 
seemed reasonable to measure the anti-BSA response as well for a negative control on the 
















Anti-(Bep-BSA) titers 44 days after primary immunization 
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Figure 24. These data are similar to Figure 22 but for the carry-over of the primary 
immunization prior to the secondary. As in Figure 21 the error bars represent the sample 
standard deviation for the individual mice; the variability is primarily an interanimal 
variability rather than an intra-assay variability. Only the upper or lower error bars are 
shown for clarity. By this time period an anti-idiotope response is seen. 
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Anti-8SA titers 44 days after primary immunization 
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Figure 25. These data are analogous to Figure 23 except for the secondary response. No 


















Anti-((9-40)F(ab'h) titers 44 days after primary immunization 









Figure 26. These data are for the anti-idiotype primary response carry-over prior to the 
secondary immunization. Only the upper or lower error bars are shown for clarity. The 
dotted line error bars are for the (Bep)-HEL cohort. 
slower than the kinetics of the anti-idiotype response. 
The secondary response is shown in Figure 27 -Figure 28. Whereas there was no 
crossreactivity in the primary response after 2 weeks, there was some crossreactivity in 
the secondary response by this time. The data are summarized in Figure 27 for each 
mouse. It should be noted in Figure 27 that the assays used necessarily differed in detail 
(coating antigens, color development times) so that the scales are only valid in a relative 
sense. Although there is very poor correlation between the anti-idiotope and anti-
idiotype responses for the mice immunized with Bep-HEL (y = 0.0853x + 0.1328; R2 = 
0.0 10 1), this cohort did have 3 out of 10 crossreacting mice, using as a criterion for 
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Figure 27. This graph summarizes the secondary response crossreactivity seen for the 
individual mice in all cohorts. 
the anti-idiotype response among mice immunized with (9-40)Fab' -HEL). One mouse 
from this group actually had a better anti-idiotype response than did any of the mice 
immunized with the intact idiotype. It is also worth noting that the anti-idiotope response 
for this mouse was the third worst of all the mice immunized with the idiotope mimic, 
surpassed only by two mice that ranked in with the negative controls. Conversely, the 
only mouse that gave some anti-idiotope response among the mice immunized with the 
intact idiotype also had the worst anti-idiotype response of all those mice. However, this 
did not remain the case; prior to the tertiary immunization, another bleeding was taken 
(due to time constraints, at 39 days for the control cohorts and at 48 days for the 





























Summary of data for 39 days (control cohorts) and 48 days 
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Figure 28. These data show the crossreactivity for the secondary immunization carry-
over. Note that the most crossreactive mouse in Figure 27 is no longer so. 
icantly, and the previously most crossreactive mouse with a low anti-idiotope response 
now had the third-highest anti-idiotope response. These data are presented in Figure 28. 
The tertiary response is shown in Figure 29. Two mice from the (Bep)-HEL 
cohort showed excellent crossreactivity and especially high anti-idiotype titers at this 
point. Even stranger, the highest anti-idiotype response of the (9-40)Fab' -HEL cohort 
was lower than the lowest response of the (Bep)-HEL cohort. The control mice appeared 
to give significant responses even at high dilutions in the ELlSAs. These could be real 
since earlier work (Chapter 4) has shown that peptides by themselves can give high titers 
after repeated immunization even at low doses, but it seems more likely that the 
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Figure 29. These data are for the tertiary immunization. The high response of the 
negative controls and the low anti-idiotype response of the idiotype cohorts was 
suspicious and motivated re-examination of the anti-idiotype responses. 
idiotope peptide but would not expect that the response would surpass that of the idiotype 
immunogen itself, as seen in the figure. 
Because of the especially low anti-idiotype titers of the Fab' -HEL cohort and also 
the high titers of the negative controls, the anti-idiotype data were fe-measured (Figure 
30). These data give results that are more consistent with what one might expect based 
on the results of the previous immunizations. The Fab' -HEL cohort gave the strongest 
anti-idiotype response. Interestingly, one of the mice in the Bep negative control cohort 
did show a strong anti-idiotype response, but the validity of this is questionable since it 
was this mouse that had the lowest anti-idiotype response in Figure 29. Otherwise it is 
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Summary of data for 16 days after tertiary immunization 
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Figure 30. These data use the same abscissa as in Figure 29 but a re-measured ordinate. 
Note that the second highest response, from a negative control mouse that exhibited the 
lowest anti-idiotype response of its cohort in Figure 29, is possibly an outlier, but it did 
not show a single well with a high absorbance but rather a nicely sloping titer. More 
importantly, it can be seen that the crossreactivity of the peptide immunogen cohort is 
fairly high (5/8 mice), using again as a criterion an anti-idiotype response of 0.2. 
worth noting that all of the Bep negative control mice had higher anti-idiotype titers than 
did all of the (Bep + HEL) cohorts. It is especially worth noting that the crossreactivity 
has increased between the second and third immunizations for the (Bep)-HEL cohort: 
311 0 crossreacti ve mice for the secondary response compared with 5/8 for the tertiary. 
Conclusions 
The specificity of the anti-idiotype response was demonstrated in a pilot study 
with BlO.A mice immunized with a (9-40)Fab'-SMCC-HEL conjugate. Those mice 
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responded well to the in1munizing idiotype and to a clonotypically related antibody 
known to be idiotypically crossreactive, but not to another anti-fluorescein antibody 
(BDCl) nor to an anti-ss(dT) antibody that shares the same framework regions as does 9-
40. It is significant that no anti-framework response was seen, since after all, those 
epitopes could also be considered part of an immunologically foreign molecule after 
coupling to HEL. This leads to speculation that the anti-framework reactive clones had 
been deleted or rendered anergic in the development of the mice' immune systems. 
A peptide mimic based on the third hypervariable region of the heavy chain of 
monoclonal anti-fluorescein antibody 9-40 and incorporating a triglycyl spacer was 
coupled to chicken hen egg lysozyme and used to generate an anti-peptide response. This 
peptide represents an idiotope of primary importance. Another vaccine based on the 
entire idiotype was also coupled to HEL and also generated an anti-idiotype response. 
Control immunogens consisting of the peptide mimic by itself or of the peptide mimic 
mixed with HEL failed to give a primary or a secondary response, although possibly gave 
a tertiary response. (Recall from Chapter 4 that peptides by themselves after repeated 
immunizations were sometimes effective at generating high titer antibody responses.) 
The kinetics of the anti-idiotype vaccine were faster than for the anti-idiotope vaccine, 
since there was an anti-idiotype response after 2 weeks but no response for the anti-
idiotope preparation. By 44 days, however, there was also an anti-idiotope response, and 
the anti-idiotype response was even stronger. The secondary response showed mild 
crossreactivity for the idiotope vaccine but only very little crossreactivity for the idiotype 
vaccine. This was also the case in the tertiary response - the idiotope vaccine resulted in 
a crossreactive response in some mice whereas the idiotype vaccine did not. 
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It seems reasonable that the anti-idiotope response should have greater cross-
reactivity than the anti-idiotype response, since there are multiple idiotopes in an idiotype 
against which a response could be directed and which would perhaps not likely be the 
accessible portions of the CDR-H3. Likewise, some of the anti-Bep antibodies are 
probably also directed against the linker or against portions of the peptide mimic that are 
not accessible in the intact idiotype. (Certainly, both vaccines doubtless elicit antibodies 
against HEL.) A more important question is why the crossreactivity for the idiotope 
peptide mimic is not initially greater than it is. Probably this is because only a few 
residues of the CDR-H3 of an antibody are exposed to bulk solvent, the rest being either 
juxtaposed to the rest of the heavy chain or forming part of the antigen binding cavity. It 
may also be the case that the anti-idiotype antibodies generated from the Pab' -HEL 
immunogen are likely predominantly rather flat in their antigen binding sites, as is 
common in cases of antibodies against proteins, whereas the anti-idiotope antibodies 
generated from the Bep-HEL are likeJyto bind the peptide in deep pockets (104). 
The present results are also consistent with earlier studies in which anti-(idiotope 
peptide mimic) antisera were generated against the CDR-H3 (22) or CDR-H2 (23). 
Those authors also reported that while one could use idiotope peptide mimics to generate 
anti-idiotype antisera, the converse did not occur. The present studies are a more direct 
comparison of the anti-idiotype response with the anti-idiotope response, since the same 
canier protein was used for both immunogens. 
Are anti-idiotope peptide mimic vaccines a promising approach to targeting 
pathological B lymphocytes? They do offer the significant advantage of being able to be 
prepared based only on the information obtainable from a biopsy followed by PCR and 
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sequenCIng, and they do have some ability to crossreact with the intact idiotype and 
probably also cause apoptosis in such B cens. Nevertheless, although the present studies 
do not specifically address lymphocyte targeting, it is clear from them that if one wants to 
target a specific idiotype, the best choice is to use the idiotype itself in some fashion to 
make it immunogenic. Such idiotype vaccines would generally be a fusion protein, an 
scFv, or a plasmid encoding such a fusion protein or scFv. Since DNA vaccines obviate 
the need for purified idiotype protein for immunogen preparation, and still allow for an 
intact idiotype to be targeted, they are a very promising alternative. Another alternative 
would be antisense, since the B cell's specificity could be exploited at the protein or the 
RNA leveL 
So what does the future hold for idiotope mimics? One very interesting question 
is whether or not a longer loop, such as the CDR-Ll or -H2 loop, would give a stronger 
response. The H3 loop was chosen primarily because it offers the most specificity, being 
the product of V -D-J gene rearrangements and not exhibiting any canonical structures. 
However, such a strong specificity requirement may be overkill, as anti-CD20 antibodies 
have shown utility in lymphoma therapy (75) and are not at all idiotype selective. In 9-40 
the CDR-H3 is rather short, so perhaps another antibody would have been a better choice 
from the standpoint of testing the CDR-H3 loop. It would be interesting to use a panel of 
antibodies with different CDR-H3 loops. 
Using such a panel could be advantageous for another reason: individualized 
therapy, as with all cancer therapy, is susceptible to failure. As noted in a footnote 
earlier, lymphocyte cancers are monoclonal at least from the standpoint of serologically 
defined surface antigens, but there can be numerous mutations giving rise to cancerous 
105 
phenotypes. Cancer therapies often result in an initial killing with survivors, likely 
mutants with only subtle differences from the clones susceptible to killing, being 
resistant. The broader issue of why tumors become resistant to drugs is still incompletely 
understood. As long as the cancer cells are monoclonal from the standpoint of expressed 
surface antigen - in the present case, the idiotype - then one would expect that a vaccine 
designed to target this antigen would still be effective even if other mutations are present 
that do not affect the idiotype expression. Indeed, this seems to be the case with the 
DNA idiotype vaccines intended to prevent relapse. If, on the other hand, small somatic 
mutations in the CDRs occur in the cancerous clones, then a panel of idiotope mimics 
could perhaps still be effective, since it is unlikely that one or a few mutations in one or 
two idiotopes would completely wipe out crossreactivity with all the idiotopes in the 
panel. 
Another consideration is the fact that the crossreactivity increases with increasing 
immunizations. This leads me to wonder if co-immunization of both an idiotope vaccine 
and an idiotype vaccine could potentially lead to a synergistic effect, and that question 
should be pursued further. Another question is at how long such increases in 
crossreactivity continue with increasing immunizations: would the idiotope vaccine ever 
exhibit as strong or as consistent an anti-idiotype response as does the idiotype vaccine? 
(Another question would be whether there would be an increase in crossreactivity to 
seemingly irrelevant antigens.) 
Another interesting area for further study is in the different kinetics of the cross-
reactive clones. The crossreactivity seen at 14 days (Figure 27) has disappeared by 48 
days (Figure 28). This is undoutedly due to the subsistence of the crossreactive clones 
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and the clearance of crossreactive antibody, but the overall anti-idiotope response at 48 
days is sti]] quite high. Is there a lack of continual stimulation of the crossreactive 
clones? Another study (18) investigating crossreactivity between an idiotope mimic and 
an intern;}] image idiotype nlimic of yet another antigen also found this same pattern of 
telnpora] crossreaclivity - there was an initial idiotope, idiotype crossreactivity that 
subsided into a nlore specific anti-idiotope response. 
Finally, the basis for the crossreactivity must lie in the antigenicity of the peptide 
rather than in any immunogenicity of the carrier protein. As shown more fully in the next 
chapter, CDR loops are quite mobile. What fraction of the 9-40 idiotype population has 
its CDR-H3 loop sufficiently exposed that i1 can be bound by anti-idiotope antibodies? 




1\10LECULAR 1\10DELING OF ANTIBODY 
BV04·01'S VARIABLE FRAGMENT 
Abstract 
We were interested in comparing different computational methodologies for 
antibody variable region structure prediction. 
Methods 
Four starting models of the variable region of monoclonal antibody BV04-01 
were subjected to 1210 ps of equilibration plus simulated annealing (SA). This was 
followed by isothermal molecular dynamics (MD) at 300 K for 2 ns for generalized Born 
(GB) implicit solvent or for 1 ns for particle mesh Ewald (PME) with explicit solvent and 
periodic boundary conditions. Because the PME methodology was more time consuming 
than was GB, the PME simulations used the results of the GB SA for the four structures 
prior to hydration and actual PME computation, except that one of these structures was 




The GB methodology resulted in a general distortion or possible twisting of the 
two chains around the antigen binding site, but with the heavy chain slightly more 
distOJ1ed than the light chain. It also showed a decrease in the accessibility to the antigen 
binding pocket of the CDR-LI and -HI loops, which were pushed away by the CDR-L3 
and -H3 loops. The four different starting structures did not converge to the same 
solution structure in the 2 ns isothermal simulation. In contrast to GB, the PME 
methodology did not cause severe distortions from the crystal structure, with the 
exception of the CDR-H3 loop, which was already removed from the crystal structure by 
the GB SA prior to hydration. 
Conclusions 
The additional computational expense of PME relative to GB for the purpose of 
solution structure prediction seems justified, but the question remains as to whether the 
deviations from the crystal structure of the CDR-H3 loop represent significantly 
populated solution substates or are merely a kinetic artifact of the SA. 
Introduction 
Recent years have seen incredible refinements of various techniques in science, 
resulting in a convergence that has greatly increased our understanding of numerous 
aspects of science, including structural biochemistry. Computational technology has 
inlproved by orders of magnitude in the last two decades, and molecular dynamics now 
plays a significant role in elucidating biochemical mechanisms and even in refining X-ray 
crystal structures (105). X-ray crystallography has played such an important role in 
structural biochemistry over the last several decades in elucidating basic biochemical 
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phenornena that it has achieved a sort of "gold standard" status, probably because high-
resolution NMR solution structures of biomolecules had a later start historically than did 
X-ray crystallography, and because many biOlnolecules are simply too large to solve by 
NMR. ]n fact, the validity of NMR as a technique for protein structure determination 
was established by X-ray crystallography as a standard, rather than vice versa (103, p. 
243-244), when the structure of the small protein tendamistat was solved by both 
techniques and was found 10 be in excellent agreement between the two. 
Determining the structure of a biomolecule is not a trivial undertaking. 
Consequently, conlputational approaches have also been explored, and with the dramatic 
increase in computer power in the last several years this is a very promising field of 
study. The ab initio prediction of tertiary structure from primary structure is still far from 
bei a robust science, but homology modeling has proven quite useful in cases for 
which significant homology does exist between proteins of known structure and the 
protein of interest of unknown structure. In fact, the primary criterion for the success of a 
homology model structure is the amount of homology that exists between the reference 
proteins and the homology model. In the case of the variable regions of antibodies, the 
framework regions are basically a]] the same, and the homology from one antibody to 
another is excellent. Because of this fact and because of their importance, a few 
homology prediction programs have been developed to obtain useful models with atomic 
detail especially for antibodies (e.g., AbM and its successor WAM (106». In any case, 
most if not all homology modeling involves several steps, ending in a final minimization 
of the predicted structure. 
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Homology model structures are usually based on crystal structures rather than 
solution structures simply because there are more of the former in the Protein Data Bank 
(PDB). Nevertheless, X-ray crystal structures (and also neutron diffraction crystal 
structures) are just that crystal structures, and it is generally the solution structure of a 
biomolecule that is of interest. As mentioned above, NMR can provide solution 
structural models for small proteins but cannot for large ones. However, the dramatic 
increases in computer power and molecular modeling in the last several years open up the 
possibility of conveJ1ing a crystal structure into a solution structure. Because in principle 
such a model could be had within an arbitrary level of error by simply increasing the 
rigor of the computations (duration of calculation, number of solvent molecules, etc.; 
even with QM caJcuJations with full CI) and no one would object to using such 
structures, and because such calculations of arbitrary exactness would generally be 
unfeasible, the germane question is, "What is the minimum requisite level of computation 
needed to establish a pJausibly realistic solution model?" To this end we used molecular 
dynamics (MD) simulations to predict the structure of the variable region of one antibody 
(BV04-0 1, for which the crystal structures of both the liganded and unliganded forms of 
the Fab fragment are known (28)), given the structure of the variable region of a 
moderately homologous antibody (4-4-20, for which severa] high resolution structures 
have been determined in different solvents (52)) using both an explicit solvent approach 
and a faster but more approximate implicit solvent approach. 
Because MD is by its very nature a time-dependent modeling approach, the 
question always will remain, What would happen if one went longer? Was the simula-
tion long enough? The general strategy we decided to follow was to use a number of 
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starling structures each with BV04-01 's sequence, and subject them all to the same set of 
molecular dynan1ics protocols. If the different structures converge to the same final 
solution structure, then that would lend credibility to the model. 
Theory of electrostatic treatments 
The function, or effect, of a dielectric is to shield charges separated by some 
distance from each other. The dielectric of a polar medium such as water is much higher 
than for a nonpolar medium such as the interior of a protein (€ = 78 for water at room 
temperature versus an estimated 4-10 for protein interiors (107)), although the value that 
should be chosen for the interior of a protein is in-defined, as occasionally there are ionic 
interactions in protein interiors. Consequently one approach to dealing with this problem 
is to replace the bulk dielectric constant with a function. The simplest function 
sometimes chosen, and what is typical1y meant by the phrase "distance-dependent 
dielectric," IS an Inverse linear relationship, but that choice is not very accurate. 
Generalized Born CGB) is a way of providing a distance-dependent dielectric function 
that is more accurate than a simple inverse linear dependence. An outline derivation 
follows (108, 109). The free energy of solvation can be thought of as the free energy 
required to form a cavity in a solvent plus solute-solvent interaction terms, generally van 
der Waals and polarization: 
G solvation = G cavity + G vdW + G polarization (1) 
The cavity and van der \Vaals tenns can be approximated by a linear function of the 
solvent accessible surface area of the solute, LyA;, where y is an empirical constant 
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related to the surface tension and Ai is the solvent accessible surface area. The 
polarization term is given by a summation of the Born equation and Coulomb's law 
(algebraically written in a fonn similar to the Born equation): 
N (1 J 1 N N qiq j (1 J 
ll.Gpolariwlio/J = I --1 +-II-- ---1 
i 2ai Cw 2 i j;t.i 'ij Cw (2) 
This gi ves the free energy of solvation as 
ll.Gsolvation = I riA; 
(3) 
where the function JGB becomes an effective Born radius in the self terms but becomes an 
effective interaction distance in pairwise terms. The most common form chosen is 
(4) 
Whereas GB is like a glorified vacuum calculation, particle mesh Ewald (PME) 
employs full solvation and is an accurate treatment of electrostatics using periodic 
boundary conditions 010-112). Briefly, the electrostatic potential <p(r) at point r is given 
by Poisson's equation: 
\1 . \1 tp(r )dr = -41lp(r) (5) 
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where per) is a smooth charge density. For periodic boundary conditions the electrostatic 
potentia] at a point r not coincident with any atomic position rj (i = 1,2, ... ,N) is given by 
summing the direct Coulomb potentia] over all atoms and all their images: 
N 
qJ(r) = II qi 
n ;=1 Ir; + nL - rl (6) 
This genera] lattice sum is conditionally convergent. Ewald's approach was to imagine 
that each charge in the crystal is surrounded by a pair of continuous charge densities: a 
counterion density and a co-ion density. Then <p(r) = <PI (r) + <P2(r). This is equivalent to 
multiplying the function by a rapidly converging function F and, to maintain equality, 
adding a term equal to the function n1ultiplied by (I-F). Ewald's insight was that the 
second term can also be made rapidly converging by a Fourier transform, giving a direct 
sum, a reciprocal sum, and a self term: 
(7) 
Essentia11y, Ewa]d summation is a periodic boundary approach that yields a neutralizing 
field of counter charge. Particle mesh Ewald is a fast Ewald sum algorithm, scaling as N 
log N (110). 
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l\1ethodo)ogy 
Choice of initial coordinates 
BV04-01 is an anti-ssdT murine autoantibody (28). It has two entries in the PDB 
for its Fab fragments: INBV and 1CBV, which correspond to the unliganded and the 
liganded states respectively. (The ligand is dT3.) 4-4-20 is a high-affinity anti-
fluorescein antibody which also has two sets of coordinates for its Fab fragment in the 
PDB: 4F AB and IFLR, both of which are for the liganded state. The 4FAB structure was 
solved to 2.70 A (113) but has been further refined and has served as the basis for MD 
simulation studies (107), whereas the 1FLR structure was solved to 1.85 A (114). 
However, both of these structures suffer from errors. The 4FAB has GLN L33 instead of 
ASN L33, and the 1FLR structure is even more problematic despite its higher resolution, 
since it completely omits residues H77 and H78, and also has L YS L24 instead of ARG 
L24. Fortunately our laboratory has produced other high-resolution structure 
determinations of 4-4-20 (52), although the data have not been deposited yet into the 
PDB. The coordinate data used herein is from the file 44p_258.pdb, for the triclinic (PI) 
structure in PEG solved to 1.78 A. 
BV04-01 differs from 4-4-20 in the third hypervariable region of the heavy chain 
in having a comletely different sequence along with three additional amino acids. Hence 
it was necessary to insert these amino acids into the CDR-H3. This was done using the 
1I1sighlII program (Accelrys, Inc.) using the 4-4-20 Fab structure. Hydrogens were added 
with 1I1sightII at pH 7.4 with the termini charged. The total charge on the molecule was 
+4. The structure was allowed to relax in the gas phase either with or without the only 
shared residue (Gly HI04) in the CDR-H3 being held fixed. (The minimization was 
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performed with the Discover program; Accelrys, Inc.) This resulted in two starting 
structures. We also decided to use the structure of liganded BV04-0 1 minus the ligand as 
another starting structure. Finally, we used the unliganded BV04-01 structure as an 
internal control. These structures are denoted herein respectively as A_struc, B_struc, 
CBV, and NBV. They each have 112 residues in the light chain and 121 residues in the 
heavy chain, with 3,566 atoms total. 
Rationale for charges 
An important issue that needs to be addressed is the validity of not using 
counterions in the simulations. The present results suggest that perhaps better agreement 
between the GB simulations and the more accurate but more time-consuming PME 
simulations could be obtained by a better treatment of the electrostatics, and that may 
include counterions. However, a priori that was unknown, since there was some debate 
in the literature when this study was begun about what is the best option for modeling: (a) 
no ions, (b) net-neutralizing (balance charge), (c) enough + and - ions to balance each -/+ 
charge in protein, or (d) excess salt (Thomas E. Cheatham, III, personal correspondence). 
For continuum ca1culations without explicit solvent, we felt that it may be better to not 
include explicit salt. Had explicit counterions been added, their van der Waals radii 
would need to have been sufficiently, large to represent a hydrated ion lest they bind 
directly and too tightly to charged residues (since there is no explicit water present). For 
the simulations in explicit solvent, there are many sources of error. Is ion presence or 
placement one of them? A much bigger source of error is lack of proper treatment of the 
electrostatics (e.g., cutoffs instead of PME). Some research has shown that net-
neutralizing is bad and that one needs to include excess salt (115), but Cheatham and 
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others have shown that in general what is more important is proper equilibration (Nephi 
Thompson and Thomas Cheatham, III, personal communication). It may have been 
better for the explicit solvent simulations to include some counterions, but since it likely 
does not have a major effect (TEC, persona1 correspondence) and since no counterions 
were added for the general Born calculations, no explicit counterions were included for 
the PME calculations either. 
InlpJicit solvent simulations 
The program AMBER 6 (116, 117) was used for all the MD in this study. 
Trajectories were analyzed primarily with the ptraj program, which is part of AMBER. 
For the generalized Born calculations the conditions were pairwise generalized Born (igb 
= 1 in AMBER), with the residues that are shared by both 4-4-20 and BV04-01 being 
restrained with a force constant of 2.0 kcal/molA. Temperature coupling was by the 
Berendsen method with Tp = 0.2. SHAKE was used with constraining bonds involving 
hydrogen. The time step for integrating Newton's equations of motion was 2 fs. For 
other details, see Appendix C. 
The simulated annealing was performed as follows: The molecules were quickly 
increased from 0 K to 1000 K in 10 ps, then held at 1000 K for 600 ps, cooled to 400 K 
over the next 300 ps, then cooled to 300 K over another 300 ps. After this period of 
simulated annealing the molecules were ran at 300 K for 2 ns with the restraints removed 
for all residues except the C termini of the two chains. The reason for this is that in a 
preliminary run the two chains rotated with respect to each other in a physically 
unrealistic way, since in a real antibody the Fv fragment is attached to the first constant 
region and therefore the two chains would not be free to rotate with respect to each other. 
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However, because the H chain C terminus is not shared between the two antibodies (Ala 
H121 in BV04-01 vs. Ser H 118 in 4-4-20, absolute numbering), it had been allowed to 
move freely during the SA so that when the constraint was applied it was trapped at the 
location at the end of the SA. (This is a fairly minor point but is the reason why the H 
chain C terminus of the crystal and solution structures do not coincide.) 
Solvated simuJations 
The next level of rigor was with explicit solvent. The molecules were hydrated 
with 8,163 TIP3 waters in a truncated octahedron shell and then relaxed (28,052 atoms 
tota1). As with the implicit solvent above, no counterions were included. The solvent 
was then relaxed with a minimization to prevent SHAKE failure and then equilibrated. 
The solvated simulations were performed under periodic boundary conditions with the 
same temperature scaling as were the GB calculations described above except that the 
initial ramping of the temperature from 0 to 1000 K was omitted due to its irrelevance 
after performing solvent equilibration. Particle mesh Ewald (PME) was used for treating 
the electrostatics. However, after performing simulated annealing on the solvated 
A_struc structure (denoted as A_solv), we decided that it would be preferable to use the 
structures resulting from the end of the sinlulated annealing under GB conditions, so 
these were hydrated with the same nu~ber of waters as had been used for A_solv, and 
then they were subjected to further isothermal MD. All the atoms were relaxed by 
minimization prior to the isothermal MD. These systems are denoted as A_solv.GB, 
B_solv.GB, C_solv.GB, and N_solv.GB. As before, the C termini of both chains were 
restrained; however, the restraint was to the position after minimization (during which no 
restraints were applied). 
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Honl01ogy nl0deHng 
An interesting question is how well this extensive and computationally expensive 
MD methodology compares with static homology modeling. Due to their importance and 
the fact that antibodies all show high homology because of their framework regions, 
considerable effort has gone into optimizing antibody honl0logy modeling programs. 
The nlost recent and probably the best of these is Web Antibody Modelling (W AM) 
(106), the successor to AbM. The sequence for the BV04-01 variable region was 
submitted to the online W AM program with the request to exclude BV04-01's own 
crystal structures from the modeling attempt. 
Results and discussion 
The root-mean-square deviations (RMSD) of the four initial structures versus the 
unliganded BV04-01 crystal structure (Fv region only, of course) for GB calculations are 
shown in Figure 31. The most obvious thing to notice from this plot is the sudden 
increase in RMSD seen when the simulated annealing ends and the restraints on the 
residues shared between BV04-01 and 4-4-20 were removed, except for the C tennini as 
noted above. In fact, it is the unliganded control structure that shows the greatest initial 
jump when the constraints were relaxed. Clearly the molecules were held in a higher 
energy state by these restraints, which would suggest that the excipients used for 
crystallization play an important role in the structure obtained. This is reasonable; if 
there are differences between the crystal and solution structures, then the excipients used 
for crystallization would favor the crystal structure over the solution structure. Previous 
research with different solvent systems for the crystallization of the 4-4-20 Fab fragment 
also shows that the nature of the solvent can affect the structure obtained (52). 
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Figure 31. All-atom minimum rms deviations for each of the four starting structures in 
comparison to the unliganded crystal structure's Fv. (Although they are completely 
invisible with the thousands of data points shown, because of run failures there are a 
handful of data missing from these runs that perhaps should be mentioned simply for the 
sakes of honesty and completeness. The restart files were fine and so the runs could 
continue with those few points being omitted.) 
Several questions are suggested by Figure 31: (1) What are the primary changes 
seen between the INBV crystal structure and the latter part of the simulated annealing, 
when the RMSD has stabilized? (2) What is the cause of the abrupt and persistent 
increase in RMSD for the CBV structure at about 275 ps? (3) Why does the A_struc 
structure, which has the same framework coordinates as does the B_struc structure (i.e., 
4-4-20's framework coordinates), have such a higher RMSD than does B_struc? One 
would expect that the simulated annealing should remove the initial differences between 
them. (4) What is the cause of the apparent departure from equilibrium at about 2500 ps 
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that seems to have been achieved by about 2200 ps for A_struc? (5) For each of these 
structures, what are the main structural features that are responsible for the changes? (6) 
Are there biases due to the modeling that account for these deformations (e.g., forcefield 
or GB solvation model)? 
Changes seen between INBV crystal structure and 
the NBV control run under GB 
The RMSD for the control run (NBV) immediately jumps from 0.35699 A (the 
crystal structure, minimized prior to SA) to a fairly constant value (-1.8 A) during the 
high temperature portion of the simulated annealing, and then at about 830 ps 
(corresponding to a temperature of 560 K) the RMSD drops to -1.6 A and remains there 
for the rest of the simulated annealing. Not surprisingly, the magnitude of the 
fluctuations is less at the lower temperatures than at 1000 K. Consequently it makes 
sense to use the region from 830 ps to 1210 ps as a basis for computing an average 
structure for comparison against the crystal structure, to see what are the immediate 
changes that result from partial removal of the restraints of the crystal structure. The 
interval from 850 ps to 1200 ps (a slightly more conservative choice) was used to 
generate an average structure. This structure differs primarily in the CDR-H3 from the 
crystal structure since that is the region with the greatest number of contiguous non-
shared residues (between 4-4-20 and BV04-01). 
Figure 32 shows the CDR-H3 loop for the crystal structure (tube representation) 
and the time averaged structure (line representation of backbone). The first four residues 
(DQTG) of the CDR-H3 loop do not differ much from the crystal structure, but the next 
five (TAWFA) are shifted away from the light chain. Trp H107 is shown in yellow for 
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Figure 32. The yellow Trp H107 is for the crystal structure whereas the purple one is for 
the time averaged structure during the latter portion of the restrained SA. The other time 
averaged structure residues are represented by a line representation of the backbone 
atoms. The heavy black tube represents the crystal structure CDR-H3 loop backbone 
atoms. This figure, and others like it, were produced with VMD 1.7.2 (Windows) (117). 
the starting structure and in purple for the time averaged structure. Surprisingly, this 
hydrophobic residue is actually more exposed to solvent than it is in the crystal structure. 
The same is true for the next residue, Phe H108 (not explicitly shown). The reason is 
probably entropic or kinetic: both Trp H107 and Phe H108 are bulky residues, and having 
been pushed out of their mostly constrained pocket by the sudden increase in temperature 
from 0 to 1000 K, may have a difficult time finding their way back in, given the greater 
degrees of rotational freedom available at the exterior of the molecule compared to buried 
in a pocket. 
At the end of the simulated annealing period there is a sudden increase in the 
RMSD for all four of the starting structures, but especially for the control run NBV. This 
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is due to the sudden removal of constraints (except for the two C tennini). The time-
averaged solution structure of the control run from 1.5 to 3.2 ns (total time, including 
simulated annealing) is shown in Figure 33 (line representation of backbone) with a best 
fit rms superposition onto the crystal structure (tube representation). This solution 
structure model exhibits a general deformation throughout most of the H chain and to a 
slightly lesser extent the L chain. Both the CDR-L1 and the CDR-HI get squeezed away 
from the antigen binding site by CDR-L3 and CDR-H3. Another significant change seen 
in the time-averaged solution structure relative to the crystal structure is in the vicinity of 
Ser H77, which flips out to the side in the solution model but is held close to the rest of 
the ~-barrel immunoglobulin fold in the crystal structure. 
Other changes seen in the GB simulations relative 
to the crystal structure 
The unliganded crystal structure is a natural choice for a reference structure, but 
so IS the time-averaged solution structure of the control run after it has reached an 
equilibrium value. From Figure 31 it could appear that three of the four structures 
converge to a common solution structure (under the GB approximation), with the 
exception of A_struc. However, the RMSD relative to this model for the four runs are 
shown in Figure 34, and from this figure it is clear that only the RMSD for the control 
run is low; the others have roughly the same amount of distortion (RMSD) with respect 
to the control solution structure (designated as NBV _av_1.5-3.2ns) as with respect to the 
crystal structure. Hence, the four structures did not converge in 2 ns of MD, or at least 
did not converge very well. The greater RMSD seen with A_struc as compared to 
B_struc is probably a result of random fluctuations, since the only difference between 
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Figure 33. Superimposed backbone Fv structures. The top view is looking down into 
the Fv's antigen binding site and the bottom view is looking from the side. The heavy, 
tubular representation is for the backbone of the crystal structure and the line 
representation is for the time averaged GB structure between 1.5 and 3.2 ns total 
simulation time. Blue represents the light chain non-CDR regions. Red represents the 
heavy chain non-CDR regions. White is the CDR-Ll, cyan is the CDR-L2, lime green is 
the CDR-L3, yellow is the CDR-HI, orange is the CDR-H2, and black is the CDR-H3. 
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GB: RMSD vs. NBV solution structure (NBV _av1.5-3.2ns) 
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Figure 34. All-atom minimum rms deviations for the starting structures compared to the 
time averaged solution structure from the NBV trajectory from 1.5 to 3.2 ns total time. 
A_struc and B_struc is the initial position of residue Gly HI04, and after the period of 
simulated annealing that difference should be completely erased, and since the RMSD for 
A_struc drops and then rises again for a brief period (-1900 to 2400 ps). These facts 
would also suggest that a much greater sampling period may be necessary to achieve 
convergence of the four starting structures, perhaps by an order of magnitude or more. 
Particle mesh Ewald simulations 
A_struc was hydrated and then simulated with explicit solvent both during the SA 
and during the isothermal portion; the structure for this run is designated as A_solv. Due 
to the time involved in simulating with explicit water rather than with GB, we decided 
that it would be a reasonable strategy to dispense with the explicit solvent during the SA, 
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in which most of the residues are restrained anyway. Hence, another set of four runs was 
done in which the starting structures for full solvation were based on the GB structures at 
the end of the SA portion of the GB runs. These structures/runs are designated as 
A_solv.GB, B_solv.GB, C_solv.GB, and N_solv.GB. They were subjected to a brief all-
atom mimimization to prevent SHAKE failure due to too high initial energies. 
Unlike the GB simulations, the RMSD vs. time relative to the unliganded crystal 
structure does not vary much (Figure 35); in fact, all the runs are essentially the same. 
The control run does have a slightly lower RMSD than do the other runs, but the 
difference is small and of marginal significance. Equilibrium seems to be reached fairly 
quickly for all four starting structures, within about 200 ps or less. The time averaged 
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Figure 35. All-atom minimum rms deviations for the starting structures compared to the 
unliganded crystal structure for the post-SA isothermal trajectories with PME conditions. 
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(over the entire isothermal MD period) solution structure for the control run is shown in 
Figure 36 superimposed on the unliganded crystal structure. The most signficant 
differences that do exist are in the CDR-H3, which could be a kinetic carryover from the 
sudden ejection of the bulky Trp Hl07 and Phe H108 from the binding pocket, or it could 
reflect a true solution state. Figure 37 shows the RMSD of the four trajectories relative to 
the PME time-averaged solution structure. Only the control run used to generate the 
solution structure shows a very low RMSD (as would be expected), but the other runs 
also show an RMSD within that typically seen for different isoforms (52) or upon ligand 
binding of BV04-01 (28). 
Figure 36. Superimposed Fv backbone structures. This figure is analogous to Figure 33 
(bottom portion) except that the time averaged structure was for the entire PME 
simulation (post-SA). Note the considerably better agreement between the two structures 
(exceot in the CDR-H3 1000. which is orobablv a carrv-over from the SA), 
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Figure 37. All-atom minimum rms deviations for the starting structures compared to the 
time averaged solution structure from the NBV trajectory. This graph is analogous to 
Figure 34 except that the curves are post-SA only and pertain to the PME simulations. 
Comparison to homology model 
The RMSD for the C-a atoms of the W AM BV04-01 Fv structure against the 
unliganded lNBV control structure was 8.0113 A and for the carbonyl atoms was 7.9279 
A (by VMD). This is a worse value than is usually the case with W AM, which can make 
homology models within the rms deviations typically seen for X-ray refinement of crystal 
structures, -2-3 A (l05). It is significantly greater than most of the distortions seen from 
GB simulations (Figure 31). The W AM model was made using the following antibodies 
as a basis: L chain: Imre, H chain: Isbs; Canonicals: Ll-L3 loops: lmre, HI loop: ldlf, 
and H2 loop: Idlf. 
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Conc1usions 
The main questions that can be addressed by isothermal MD simulations on a 
biological macromolecule are (l) Does the molecule move much relative to its canonical 
(e.g., crystal) structure? and (2) If it does move, then how and where? The present results 
indicate that the generalized Born implicit solvent model disagrees substantially in the 
solution structure predictions relative to the case with explicit solvent, which has close 
agreement to the crystal structure. The GB distortions appear throughout the entire H 
chain as well as in the CDR-Ll loop of the light chain, and to a slightly lesser extent 
throughout the majority of the light chain as well. Severe discrepancies between solution 
and crystal structures are rare, and given the good agreement between the PME 
simulations and the crystal structure, as well as the fact that all four PME solution 
structures agree with each other, at first glance it seems likely that the PME structures 
may accurately represent the sol ution structure and that the distortions seen in the GB 
runs are artifacts of the GB methodology. In particular, the distortion seen with GB is 
probably due to too severe approximation inherent in the GB model, as well as the fact 
that the total charge on the molecule was +4. Had implicit counterions been included, 
then perhaps less distortion relative to the case of full solvation might have been seen. 
Also, generalized Born is not a periodic boundary simulation condition, unlike PME. 
This probably contributes to the distortion by allowing charged surface-exposed side 
chains to seek to minimize their repulsions, resulting in a twist of the molecule. 
The bane of all MD studies is the question of how long is long enough. The 
present study incorporates an objective means of answering that: four slightly different 
initial configurations were used to generate trajectories that at equilibrium and averaged 
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over a sufficiently long interval should be indistinguishable. While the difference is 
small for the PME.GB runs, it is significant for the GB runs, about the same as the 
distortion seen in going from the unliganded crystal structure to the control run solution 
structure NBV _av_I.5-3.2ns. Most disturbing is the fact that the GB structures did not 
converge in 2 ns, so the apparent semi-convergence of the PME structures in 1 ns is 
possibly fortuitous. The sinlulation time needed to adequately sample the accessible 
configuration space, and hence to achieve equilibrium, ought to be independent of 
whether the solute is exploring its configurational space in explicit or implicit solvent. 
However. it is known that GB simulations sample conformations faster than do PME 
calculations due to the lack of viscous solvent resistance. This is an advantage from the 
standpoint of expJoring conformational space but is a disadvantage if one is primarily 
interested in accurate dynamics. Similar problems with GB in which a known solution 
structure (of thioredoxin) is known by NMR to be in close agreement with its crystal 
structure but is distorted by OB have been noted (119), 
The initial question posed was, "What is the minimum requisite level of 
computation needed to establish a plausibly realistic solution model?" From the present 
results it would seem that full solvation under periodic boundary conditions using particle 
mesh Ewald treatment of electrostatics would be the preferred methodology; generalized 
Born was too severe an approximation - at least without implicit counterions. But the 
ideal way to answer this question would be to carry out a number of simulations with 
different levels of rigor and then to compare them to a known solution structure. For that 
a different protein choice may be optimal, particularly one that is known to exhibit 
differences between the solution and crystal structures. However, recent advances in 
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NMR structure determination with isotopic enrichment have pushed the size 1imit for 
determining structure to about 50 kDa (120), so that it may actually be possible to solve 
the solution structure of the Fab fragment of BV04-01. 
A caveat to the entire hypothesis of being able to compute solution structures 
given crystal structures is the time scales involved: weeks to months for crystallization, 
picoseconds to nanoseconds for MD. It is entirely possible that the solution structures 
that were detemlined in this paper are metastable. This is especially suggested by the 
increase in solvent exposure of Trp HI07 and Phe RI0S resulting from the simulated 
annealing. However, the potential for metastability is and probably always will be a 
caveat to most MD studies (e.g., the persistence of B-RNA in (121)); it is not likely that 
this caveat can be overcome in the near future. Simulated annealing can in principle 
overcome the problem of metastability, but without constraints or restraints would instead 
result in a general protein folding problem, which is not feasible to solve by this method. 
Since the solutions could be metastable, it would be very interesting to see if they are 
supported by NMR. 
In the case of antibodies, a very recent paper has appeared that does indicate 
differences between solution structures of llama heavy chain variable (VHH) domains 
(122). (Camelids produce antibodies that lack light chains.) In that paper the solution 
structure of a 117 residue VHH was solved by NMR. (For comparison, the Fv's used 
herein are 233 residues.) The authors compared the solution structure with the previously 
determined crystal structure and found a high similarity to the framework but significant 
conformational differences in the CDRs, and concluded that the antigen recognition site 
is a more mobile part. The present results would support the conclusion that the antigen 
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recognition site is more mobile, but some differences were also observed with the 
framework regions. An even more recent paper describes the solution structure of a 
llama heavy chain antibody and finds that the loop regions, especially the H3 loop, are 
more mobile (123). 
How does all this affect antigenicity? As mentioned in Chapter 2's modeling, the 
conformation of a peptide is crucial to its antigenicity; the shape the immune system sees 
wil] determine which B cel1s are capable of binding the antigen. If the CDR-H3 loop 
does in fact exhibit a significant portion of its time exposed, then it is probably more 
accessible for binding by anti-idiotope antibodies. Hence, a knowledge of the solution 
structure would be useful for predicting the antigenic qualities of various epitopes. 
CHAPTER 7 
CONCLUSIONS AND FUTURE WORK 
Whereas in previous chapters conclusions pertinent to that chapter were presented 
in their context, in this chapter my goal is to draw together the work as a whole and to 
suggest areas of future endeavor. Chapter 2 introduced me to molecular modeling, 
protein derivatization, fluorescence spectroscopy, cell culture, animal handling, 
chromatography, electrophoresis, dynamic light scattering, and various other laboratory 
techniques, as well as experimental design and data analysis. While this was personally a 
tinle of scientific growth, the end result was that BV04-0I was a difficult protein with 
which to work - the yield or the analysis of the idiotype, carrier protein conjugate was 
unsatisfactory, and we decided to abandon BV04-0I in favor of an IgGI mAb, 9-40, for 
which the requisite chemistry and analysis went much smoother. 
T cell epitope mimicry 
Chapter 3 dealt with the use of chicken hen egg lysozyme (HEL) as a carrier 
protein, compared to its immunodominant T cell epitope in a given mouse strain (BIO.A). 
That research showed that the T cell epitope completely failed to replace its parent carrier 
protein and suggested the work in Chapter 4, a dose response study using the same T cell 
epitope. That study examined the T cell epitope by itself (with fluorescein attached as the 
B cell epitope against which antibodies were raised), the T cell epitope incorporated into 
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a "tetrameric" multiple antigen peptide (MAP) construct, and as part of the carrier 
protein. A control MAP was also made but with the T cell epitope sequence replaced by 
glycine residues. Further analysis showed that the control MAP was in fact mostly 
tetrameric with a minor dimeric component, whereas the experimental MAP was mostly 
dimeric with a minor tetrameric component. Hence, one rather pragmatic conclusion is 
to not trust a vendor's analysis and labeling of a MAP without first preparing and 
analyzing a short test peptide sequence with the resin in question. More immunologically 
important was the result that incorporation of a T cell epitope into a branched oligomer 
such as a MAP greatly increased its potency, at least 300 fold, making it indistinguishable 
from the carrier protein over the concentration range examined. This confirms and 
extends in a quantitative fashion numerous other MAP papers. 
It also is the most promising area of future wet lab experiments arising out of my 
research. For example, some questions that these results suggest are: 
(1) What is it about oligomerization that causes the T cell epitope's potency to 
increase? Is it a matter of more efficient antigen uptake? If so, predominantly by which 
cells, and how is efficiency increased? Or is it a matter of more effective antigen 
processing and presentation? Again, if that is the case, why? The use of fluorescent dyes 
as model B cell epitopes, coupled to a T cell epitope of interest, as in my present studies 
but with purity of branched products, would be a good model system for further study in 
this area. 
(2) From a pharmaceutical perspective, would another oligomer or polymer be a 
better choice than a MAP? One could easily envisage a polymeric backbone to which are 
attached T and B cell epitopes as pendant groups. Again, the choice of a dye such as 
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fluorescein as a B cell epitope would probably be an excellent one for furthering these 
studies. The present T cell epitope, for B 10.A mice, could continue to be used to extend 
these studies more directly, or another T cell epitope could be used. One such epitope 
would be the immunodominant epitope of HEL in BALB/c mice (H_2d), since that strain 
recognizes only one epitope from HEL, p107-120 (45). (In fact, that strain would have 
been a better choice for the present studies except for the fact that its epitope has both 
Cys and Lys. Lys could complicate comparison to HEL derivatized via its Lys side 
chains, and Cys could potentially cause solubility and analysis difficulties with MAPs. 
Those are probably not insurmountable complications, but given the unexpected 
difficulties with BV04-01 we felt that it would be better to use the B 10.A strain and 
epitope.) 
(3) As discussed in Chapter 1, peptide vaccines are more promising for certain 
conditions than for others - in particular, for autologous antigens, such as for cancer 
vaccines, and for pathogens that have repeating peptide units and that are difficult to 
culture, such as malaria parasites. For some illnesses, a Thl response is efficaceous, 
whereas for others a Th2 response is needed (104). Can one influence the type of 
immunity by the type of polymeric carrier? Besides providing a quantitative 
magnification of the humoral response, is there a qualitative change with epitope 
oligomerization that also occurs, which one could exploit to provide the most appropriate 
type of immunity for a given malady? 
(4) The secondary response was real1 y no better than the primary response at 2 
weeks for most of the cohorts. Why was this? The secondary response did increase 
further and at 56 days the response was still quite high. There is no guarantee that the 
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four immunogens examined exhibit the same kinetics, nor that the kinetics is independent 
of the dose. These questions warrant further study. 
B ceJJ epitope mimicry 
Chapter 5 examined the response obtained from immunizing with an idiotope 
peptide mimic based on the third complementarity determining region of the heavy chain, 
the CDR-H3, with the response obtained from immunizing with the parent idiotype, 
conjugated to the same carner protein as that to which the idiotope peptide mimic was 
conjugated (HEL). The results showed that (1) an idiotope vaccine did result in 
crossreactive antisera in some animals, (2) the converse was not true (or barely so) - an 
idiotype vaccine did not elicit antisera that recognized the idiotope peptide mimic, (3) the 
number of crossreactive mice increases with increasing immunizations, and (4) the anti-
idiotype response from the idiotype vaccine is more consistent and overall stronger than 
the anti-idiotype response from the idiotope vaccine, so that if one wants to target 
pathologica] B cells expressing a given idiotype, an anti-idiotype vaccine is a better bet 
than is an anti-idiotope vaccine. This wouJd suggest that future work for idiotype 
targeting proceed along the lines of DNA vaccination, antisense therapy, and genetically 
engineered idiotype expressing proteins (single chain variable fragment (scFv), phage 
display, and the like). 
Of course, one could also pursue both anti-idiotype and anti-idiotope 
immunotherapies in order to achieve exquisite specificity and perhaps synergy. That has 
not been examined. It wouJd also be worthwhile to examine other CDR loops besides the 
H3 loop for crossreactivity, in particular the Ll and H2 loops, which are also rather large 
and exposed. Would crossreactivity be increased by using a cocktail of CDR antigens in 
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the vaccine? If so, that would fit in well with some of the potential polymeric constructs 
mentioned above in the T cel1 epitope mimicry conclusions and future work. 
On a more basic science level, one question suggested by the present results is, 
"Why does the crossreactivity increase with increasing immunizations?" Increasing 
crossreactivity is not the same as increasing affinity (i.e., affinity maturation), yet it 
seems likely that these events are somehow related. Is the increase in crossreactivity 
merely an accident of the immune system trying out different antibodies? That seems to 
be the most reasonable explanation at present. 
The question of the accessibility of the CDR-H3 to cognate antibodies is an 
interesting issue. In what fraction of 9-40 molecules is the CDR-H3 loop exposed? 
Chapter 6 includes simulations for BV04-01 that suggest that the CDR-H3 in solution can 
be exposed rather than buried as a wall of the antigen binding pocket. Is this real, and if 
so, is this what is needed for crossreactivity? It would be interesting but probably 
difficult to identify the fraction of the population of Id that is exposed in its CDR-H3. 
Molecular modeling can probably be useful in this regard by calculating the free energy 
difference between the exposed and the buried states. 
Computational studies in idiotypy 
Chapter 6 continues the theme of idiotope and idiotype studies by molecular 
modeling, in a sense coming full circle back to the beginning of this project. Although 
idiotope mimicry by peptide vaccines may not be the immunotherapy of choice, 
modeling antibody variable regions is still a very promising academic endeavor with the 
potential to be applied to peptide-MHC and TCR-peptide-MHC complexes (124, 125) 
and other areas. Some questions suggested by the present results are: 
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(1) Is locally enhanced sampling (LES) a superior way of predicting CDR loops 
than SA? LES is a mean field methodology in which additional computational effort is 
expended towards a region of interest - often loop regions of globular proteins - thereby 
a]]owing increased sampling of this region relative to the sampling that would be found in 
typical room temperature nanosecond timescale simulations (116, 126, 127). It 
essentially allows one to get multiple trajectories from a single simulation by replacing 
the regions of interest with multiple copies which are free to move apart and explore 
different regions of conformational space. It also lowers the barriers to conformational 
transitions, resulting in more frequent conformational changes. This should avoid the 
issue of the potential artifact of CDR-H3 loop motion due to the SA. 
(2) Would MD with different counterions and protonation states give greater 
consistency between the generalized Born (OB) results and the particle mesh Ewald 
(PME) results? This opens up an entire set of simulations in which pH and ionic strength 
can be varied and compared to measured values of antibody affinity. 
(3) Can one take the time-averaged solution structures obtained herein and re-
create the crystal structure of unliganded BV04-01 with explicit modeling of the 
crystallization excipients? Likewise, can one reproduce by simulation the differences 
seen in the Fab fragments due to different crystallization milieus for 4-4-20 (52)? 
(4) How much is Ag binding site flexibility diminished upon Ag binding? This is 
a fascinating question that has been touched upon in earlier computational work 
involving 4-4-20 (l 07, 128). A comparison of various antibody-antigen complexes 
shows that some utilize induced fit and others utilize more lock-and-key (128). What are 
the structural parameters that determine this, and how are they manifested in the 
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dynamics of the Fv? Is this why 4-4-20 crystallizes easier with antigen? Such studies, 
combined with NMR, could also support or refute a neo-instructional theory suggested by 
observations that an scFv of anti-fluorescein antibody 9-40 has different affinities for 
fluorescein depending on whether, how recently, and how long it has been exposed to 
antigen (Prof. David M. Kranz, University of Illinois at Urbana-Champaign, Prof. James 
N. Herron, personal communication). 
(5) Can one experimentally verify or refute the MD solution structures (either the 
BV04-01 structures presented herein or another set of structures, e.g., a 9-40 scFv) with 
NMR? 
(6) Can one use free energy calculations with the appropriate antigen for 4-4-20 in 
different solvent systems, for the W AM model of 9-40, or for BV04-01 crystal or time 
averaged solution structures to provide an excellent measure of the validity of the 
mode1ing? Likewise, could one correlate alpha carbon RMSD to A G, as per reference 
(129)? Can one achieve the two goals mentioned in (129) - high resolution structural 
refinement and accurate ranking of model predictions? 
APPENDIX A 
SOME MISCELLANEOUS SYNTHESES AND OBSERVATIONS 
FROl\1 WET LAB WORK WITH BV04-01 AS THE FOCUS 
Kinetics of antibody oxidation with NaI04 
Monoclonal antibody 9-40 was used in this kinetics study of carbohydrate 
oxidation instead of BV04-01 in order to save on the available BV04-01. Although these 
antibodies are from different classes (IgGl vs. IgG2b respectively), they probably would 
not exhibit very different kinetics of NaI04 oxidation. The data are fitted to a pseudo-
first order function and plotted in Figure 44. The pseudo-first order rate constant is k = 
0.05347 h- l (95% CL [univar]: 0.022 to 0.085 h- l ), according to the statistical summary 
from Scientist v. 2.0 (MicroMath, Inc., now defunct). Unlike another report (130) 
studying the kinetics of periodate oxidation but using polyclonal rabbit antibodies, the 
present results with nlonoclonal murine antibody 9-40 do not seem to require postulation 
of two classes of sites; a single class of sites appears satisfactory. 
Instabilitv of hydrazone linkage to oxidized antibody 
Fluorescent dyes containing hydrazide or maleimide functional groups were used 
in diagnostic reactions to probe the unsuccessful IgGoX -MPBH + SPDP-HEL reaction 
mentioned in Chapter 2. For the hydrazide dyes, two were used: Lucifer yellow 
(Molecular Probes, Eugene, OR) and FL-MPBH. For the latter, SAMSA-FL (Molecular 
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Kinetics of 9-40 (/gG 1) oxidation with NalO4 
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Figure 38. The antibody 9-40 (6.68 mL of 4.20 mglmL) was oxidized at room 
temperature in the dark (according to a protocol from Pierce, although oxidations in the 
light seem to have proceeded quite satisfactorily) with a 1000-fold excess (42.1 mg) of 
NaI04 . At 0, 15, 30, 45, 60, and 90 min an aliquot (l.34 mL) was removed and put into 
an Eppendorf tube containing 20 JlL of glycerol and vortexed to quench further 
oxidation. These samples were then passed through a Superdex 75 size exclusion column 
(Amersham Pharmacia) and eluted with 0.1 M NRtAc, pH 5.5, then concentrated. Then 
to each reaction was added 200 JlL of Lucifer yellow (LYon ordinate) stock solution (1.3 
mg of Lucifer yellow in 1.0 mL of water, -13-fold excess of Lucifer yellow). The next 
day this was passed through a PD-IO size exclusion column (Amersham Pharmacia) and 
the degree of labeling analyzed by UV/VIS spectroscopy. 
Probes) was reacted with base according to the manufacturer's instructions. The 
resulting FL-SH was then reacted with MPBH, giving a hydrazide derivative of 
fluorescein (MPBH-FL) (Figure 39), which was reacted (in pH 5.5 0.1 M ~Ac) with 
IgGOX , prepared as described above. (This also demonstrates the expected reactivity of 
the resulting aldehydes.) The fact that the MPBH reacted as it did with the activated 
SAMSA fluorescein strongly implies that the MPBH was fine, at least with regards to its 
IgGox-MPBH-FL degradation, PBS pH 7.5, 296 K 
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Figure 39. Reacting MPBH-FL with the oxidized IgG (designated IgGoX) gave a 
fluorescent product, as expected, but it was unstable. (Almost certainly the degradation 
reaction is hydrolysis.) After removing the free MPBH-FL from the IgGoX by size 
exclusion chromatography (SEC), the fluorescence polarization of the dye was measured 
as a function of time using a macro written in the ISS software (ISS, Inc., Champaign, IL) 
and found to decay according to a first-order equation with rate constant k = 0.19 h- 1• 
maJeimide group, and the fact of the reactivity with IgGoX shows it was fine with regards 
to its hydrazide group. The satisfactory synthesis of HS-HEL was shown by its 
conjugation to fluorescein maleimide. That would leave in question only the reactivity of 
IgGoX -MPBH with HS-HEL - precisely the desired reaction. 
Lucifer yellow was also reacted with IgGoX and the kinetics were followed (Figure 
40). It seems that with Lucifer yellow the nitrogen a to the carbonyl closer to the dye 
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Figure 40. Degradation of (9-40)IgGoX -(Lucifer yellow). Lucifer yellow (Molecular 
Probes), another fluorescent dye possessing a hydrazide group, was more stable (but 
unfortunately the rate constant determined for that system had a poorly defined to, so that 
the parameter values were too uncertain to be worth reporting). Note the longer time 





I~ NH N IgGox~N/ y 
o 0 
Figure 41. The hydrazone linkage formed by MPBH-FL (top) is less stable (easier to 
hydrolyze) than that formed by Lucifer yellow (bottom). 
Synthesis and characterization of the homobifunctional 
crossJinker 1,5-bis-(p-nitrophenylformyl)pentane 
p-Nitrophenylate (pNP) is a convenient leaving group because its bright yellow 
color allows easy visual assessment of reaction progress. Because no suitably spaced 
commercially avaiJable amine reactive homobifunctional crosslinker containing this 
group was found, 1 ,5-bis-(p-nitrophenylformyl)pentane was prepared by derivatizing 1,5-
pentanediol with p-nitrophenylchloroformate. A 2.05: 1 molar excess of the latter (8.6362 
g), dissolved in 26 mL of toluene, was added to the former (1.9751 g; nominally 96% 
pure, the balance being mostly water), to which was then added 24 mL of anhydrous 
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THF. The resulting crystals were washed with hexane and dried, then stored sealed in a 
freezer. A small quantity of the material was dissolved in THF, spotted onto a silica TLC 
strip, and eluted with hexane: chloroform: ethyl acetate (2: 1: 1) as a single spot. Proton 
NMR (Figure 42) was used to confirm the structure of the 1,5-bis-(p-nitrophenylformyl)-
pentane product (Figure 43). 
Fluorescein as a leaving group 
Various diagnostic experiments using fluorescent dyes together suggested that 
fluorescein attached by an amide linkage to Lys side chains (via reaction of fluorescein 
NHS ester to HEL) was unstable to nucleophiles such as 2-mercaptoethanol (2-ME) or 
hydrazine (Hz). FL-HEL was made using 5-FAM (i.e., fluorescein NHS ester -
Molecular Probes, Eugene, OR) and later treated with 2-mercaptoethanol and heat or with 
hydrazine at room temperature or just left alone (Figure 44). The conditions used can 
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Figure 42. IH NMR verification of 1,5-bis-(p-nitrophenylformyl)pentane synthesis. 
Panel A is the full spectrum taken (with the sample dissolved in deuterated chloroform). 
Panels Band C are expanded views and follow on succeeding pages. 
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Figure 42, continued. Aliphatic region of the spectrum of 1,5-bis-(p-nitrophenyl-
formyl)pentane. 
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1 ,5-bis-(p -nitrophenylformyl)pentane 
(or simply pentyl-(pNPh) 
Figure 43. Structure of a homobifunctional crosslinker prepared in this work. 
Lane: 1 2 3 4 5 6 
Figure 44. PhastGel IEF 5-8 prior to staining. Lane 1 is untreated HEL-FL; lanes 2, 3 
were treated with 2-ME and heated -15 min at 90-92 cC, lanes 4, 5 were as lane 1 except 
diluted 1 :2, and lane 6 was treated at room temperature with Hz. Note that HEL, which 
has a very high pI (-10), still has a sufficiently high pI after derivatization with dye to put 
it entirely at the negative electrode (the bottom of the gel), whereas free fluorescein is 
acidic and migrates at the top of the gel. The samples were applied in the middle of the 
gel (visible as an artifact). 
APPENDIXB 
EXTINCTION COEFFICIENTS OF SOME SPECIES USED 
Based on the counted Trp (W), Tyr (Y), and Phe (F) content of the antibodies and 
their Fabs, E are as follows: 
Protein W Y F M.W. M-1 -] E, cm E, (glLr] cm-1 
BV04-01 26 50 44 150,000 225,268 1.5018 
BV04-01 Fab 9 18 15 47,588 78,915 1.6583 
9-40 28 52 52 150,000 240,884 1.6059 
9-40 Fab 9 22 14 47,600 84,398 1.7731 
9-40 Fab-HEL, 1: 1 conjugate 15 25 17 62,300 122,849 1.9719 
4-4-20 28 58 42 150,000 247,434 1.6496 
4-4-20 Fab 10 22 14 47,600 89,998 1.8907 
HEL 6 3 3 14,314 38,100 2.2 
APPENDIX C 
AMBER INPUT FILES USED FOR GB AND 
PME SIMULATIONS 
Here is a sample input file (for NBV), used with simulated annealing: 
JSC's GS S.A. file, for use after GB minimization on entire molecule 
&cntrl 
timlim 9999999, nmropt::: I, 
ntpr ::: 500, ntwx 500, ntwe::: 500, 
ntwr == 500, 
ntb = 0, igb == I, 
ntr ::: J, tautp == 0.2, 
nSllim 25000, dt = 0.002, ntc::: 2, ntf = 2, 
nU ::: J, tempi = 0.0, 
&end 
&wt type = 'TEMPO', istepl == 0, istep2 = 5000, 
value J 0., value2 = 1000., &end 
&wt type = 'TEMPO', istepl::: 5001, istep2 = 25000, 
valuel 1000., value2 = 1000., &end 




AP-N Ll to LEU L38 
2.0 
RES I 38 
END 
TRP LAO to L YS+ LSO 
2.0 
RES 40 50 
END 
LEU L52 to PRO LlOO 
2.0 
RES 52 100 
END 
THR Ll02 to GLY Ll04 
2 
RES 102 104 
END 








GL-N HI to VAL H2 
2 
RES 113 114 
END 
GLU- H6 to PRO H 14 
2 
RES 118 126 
END 
LYS+ HI9 to CYS H22 
2 
RES 131 134 
END 

















L YS+ H43 to ALA H49 
2 
RES 155 161 
END 
ILE H51 to ARG+ H52 
2 






ASN H57 to TYR H58 
2 
RES 169 170 
END 
THR H60 to TYR H62 
2 
RES 172 174 
END 
ASP- H64 to L YS+ H67 
2 
RES 176 179 
END 
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ARG+ H69 to SER H77 
2 
RES 181 189 
END 




GLU- H91 to ASP- H92 
2 
RES 203 204 
END 




TYR HIlO to THR HilS 
2 
RES 222 227 
END 
VAL HI17 to SER HI20 
2 
RES 229 232 
END 
END 
Here is a sample input file (for NBV) used with simulated annealing: 
JSC's GB isothermal run, 3010 - 3210 ps: 
&cntrl 
nmropt = I, 
ntpr = 500, ntwr 500, ntwx = 500, ntwe = 500, 
ntb = 0, igb J, 
ntr = I. taUIp 0.2, 
nstlim = 100000, dt = 0.002, ntc = 2, ntf = 2, 
nit I, tempi = 0.0, 
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&end 
&wt type = 'TEMPO', istepl I, iSlep2 ::: 100000, 
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